Brand_name,Drug_name_original,Drug_name,DrugId,targetIds,Sponsor,Properties,TA,TA_check,Indication,Indication_EFO,DiseaseId,Review_type,Year,has_GE,comment,Disease_class
Accrufer,Ferric maltol,FERRIC MALTOL,CHEMBL4298110,NA,Shield Therapeutics,Iron replacement product,Other,No human target,Iron deficiency anaemia,iron deficiency anemia,HP_0001891,S,2019,NA,,Non Severe
Adakveo,Crizanlizumab,CRIZANLIZUMAB,CHEMBL4297734,ENSG00000174175,Novartis,P-selectin blocker,Other,Other indication,Painful complications of SCD,sickle cell disease and related diseases,MONDO_0017146,"P, O, B",2019,FALSE,Symptomatic,Severe
Adbry,Tralokinumab,Tralokinumab,CHEMBL1743081,ENSG00000169194,LEO Pharma,IL-13-targeted mAb,Other,Other indication,Atopic dermatitis,atopic eczema,EFO_0000274,S,2021,TRUE,,Non Severe
Addyi,Flibanserin,FLIBANSERIN,CHEMBL231068,"ENSG00000178394, ENSG00000102468, ENSG00000069696",Sprout,Serotonin receptor modulator,Other,Other indication,Hypoactive sexual desire disorder,sexual dysfunction,EFO_0004714,S,2015,FALSE,,Non Severe
Adempas,Riociguat,RIOCIGUAT,CHEMBL2107834,"ENSG00000123201, ENSG00000164116, ENSG00000061918, ENSG00000152402",Bayer,Soluble guanylyl cyclase stimulator,Other,Other indication,Persistent or recurrent chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension,pulmonary arterial hypertension,EFO_0001361,"P, O",2013,TRUE,,Severe
Adlyxin,Lixisenatide,LIXISENATIDE,CHEMBL2108336,ENSG00000112164,Sanofi,GLP1 receptor agonist,Other,Other indication,Diabetes,diabetes mellitus,EFO_0000400,S,2016,TRUE,,Severe
Aduhelm,Aducanumab,Aducanumab,CHEMBL3039540,ENSG00000142192,Biogen/Eisai,Amyloid-beta-targeted mAb,Other,Other indication,Alzheimers disease,Alzheimers disease,MONDO_0004975,"P, A, F",2021,TRUE,,Severe
Aemcolo,Rifamycin,RIFAMYCIN,CHEMBL437765,NA,Cosmo Technologies,Ansamycin antibacterial,Other,No human target,Travellers diarrhoea,Diarrhea,HP_0002014,"P, F",2018,NA,,Non Severe
Aimovig,Erenumab,ERENUMAB,CHEMBL3833329,ENSG00000064989,Amgen/Novartis,CGRP receptor antibody,Other,Other indication,Migraine,migraine disorder,MONDO_0005277,S,2018,TRUE,,Non Severe
Ajovy,Fremanezumab,FREMANEZUMAB,CHEMBL4297756,"ENSG00000110680, ENSG00000175868",Teva,CGRP antibody,Other,Other indication,Migraine,migraine disorder,MONDO_0005277,P,2018,TRUE,,Non Severe
Aklief,Trifarotene,TRIFAROTENE,CHEMBL3707313,ENSG00000172819,Galderma,Retinoic acid receptor agonist,Other,Other indication,Acne vulgaris,acne,EFO_0003894,S,2019,FALSE,,Non Severe
Akynzeo,Netupitant; palonosetron,NETUPITANT; PALONOSETRON,CHEMBL206253; CHEMBL1189679,ENSG00000115353; ENSG00000166736,Helsinn,An NK1-receptor antagonist plus a 5-HT3-receptor antagonist,Other,Other indication,Chemotherapy-related nausea,Chemotherapy-induced nausea and vomiting,EFO_0006911,S,2014,FALSE,Symptomatic,Non Severe
Akynzeo IV,Palonosetron; fosnetupitant,PALONOSETRON; FOSNETUPITANT,CHEMBL1189679; CHEMBL3989917,ENSG00000166736; ENSG00000115353,Helsinn Group,5-HT3-receptor antagonist and NK1-receptor antagonist,Other,Other indication,Chemotherapy-induced emesis,Chemotherapy-induced nausea and vomiting,EFO_0006911,S,2018,FALSE,Symptomatic,Non Severe
Alecensa,Alectinib,ALECTINIB,CHEMBL1738797,"ENSG00000171094, ENSG00000143924, ENSG00000165731",Roche,ALK inhibitor,Oncology,Oncology,NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A",2015,TRUE,,Severe
Aliqopa,Copanlisib dihydrochloride,COPANLISIB,CHEMBL3218576,"ENSG00000171608, ENSG00000121879",Bayer,PI3Kalpha/‚Äö√¢√†‚àö‚â†¬¨¬®‚Äö√Ñ¬¢ inhibitor,Oncology,Oncology,Follicular lymphoma,follicular lymphoma,MONDO_0018906,"P, O, A, F",2017,TRUE,,Severe
Alunbrig,Brigatinib,BRIGATINIB,CHEMBL3545311,"ENSG00000171094, ENSG00000146648",Ariad Pharmaceuticals/Takeda,ALK inhibitor,Oncology,Oncology,ALK-positive NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A",2017,TRUE,,Severe
Amondys 45,Casimersen,Casimersen,CHEMBL4297566,ENSG00000198947,Sarepta,Exon 45-skipping ASO,Other,Other indication,DMD,Duchenne muscular dystrophy,MONDO_0010679,"P, O, A, F",2021,TRUE,,Severe
Amvuttra,Vutrisiran,Vutrisiran,CHEMBL4594511,ENSG00000118271,Alnylam,TTR-targeted siRNA,Other,Other indication,Polyneuropathy of hereditary TTR-mediated amyloidosis,familial amyloid neuropathy,EFO_0004129,"S, O, F",2022,TRUE,,Severe
Annovera,Segesterone acetate; ethinyl estradiol,SEGESTERONE ACETATE; ETHINYL ESTRADIOL,CHEMBL3707377; CHEMBL691,ENSG00000082175; ENSG00000091831,TherapeuticsMD,Progestin and estrogen combined hormonal contraceptive,Other,Other indication,Female contraception,contraception,EFO_0009520,S,2018,TRUE,,Non Severe
Anoro Ellipta,Umeclidinium; vilanterol,UMECLIDINIUM; VILANTEROL,CHEMBL1187833; CHEMBL1198857,ENSG00000133019; ENSG00000169252,GSK,Anticholinergic and a LABA,Other,Other indication,Chronic obstructive pulmonary disease,chronic obstructive pulmonary disease,EFO_0000341,S,2013,TRUE,,Severe
Anthim,Obiltoxaximab,OBILTOXAXIMAB,CHEMBL3544926,NA,Elusys Therapeutics,mAb against anthrax toxin,Other,No human target,Anthrax,anthrax infection,EFO_0000778,"S, O, F",2016,NA,,Severe
Aptiom,Eslicarbazepine,ESLICARBAZEPINE,CHEMBL315985,"ENSG00000168356, ENSG00000169432, ENSG00000144285, ENSG00000007314, ENSG00000136546, ENSG00000185313, ENSG00000136531, ENSG00000183873, ENSG00000196876, ENSG00000153253",Sunovion,"MOA unknown, but thought to involve voltage-gated sodium channels",Other,Other indication,Partial-onset seizures,Seizure,HP_0001250,S,2013,TRUE,,Not concordant
Aristada,Aripiprazole lauroxil,ARIPIPRAZOLE LAUROXIL,CHEMBL2219425,"ENSG00000102468, ENSG00000178394, ENSG00000149295",Alkermes,Extended release atypical antipsychotic,Other,Other indication,Schizophrenia,schizophrenia,MONDO_0005090,S,2015,TRUE,,Not concordant
Artesunate,Artesunate,ARTESUNATE,CHEMBL361497,NA,Amivas,Artemisinin antimalarial,Other,No human target,Severe malaria,malaria,EFO_0001068,"P, O, B, F",2020,NA,,Severe
Asparlas,Calaspargase pegol,CALASPARGASE PEGOL,CHEMBL2108728,ENSG00000166183,Servier,Asparagine specific enzyme,Oncology,Oncology,ALL,acute lymphoblastic leukemia,EFO_0000220,"S, O",2018,FALSE,,Severe
Austedo,Deutetrabenazine,DUTETRABENAZINE,CHEMBL3137326,ENSG00000165646,Teva,VMAT2 inhibitor,Other,Other indication,Chorea associated with Huntington disease,chorea; Huntington disease,EFO_0004152; MONDO_0007739,"S, O",2017,TRUE,,Severe
Avycaz,Avibactam; ceftazidime,AVIBACTAM; CEFTAZIDIME,CHEMBL1689063; CHEMBL44354,NA; NA,Allergan,A beta-lactamase inhibitor and a cephalosporin,Other,No human target,Complicated intra-abdominal infections and complicated urinary tract infections,infection,EFO_0000544,"P, F",2015,NA,,Severe
Axumin,Fluciclovine F-18,FLUCICLOVINE F-18,CHEMBL3707267,"ENSG00000155465, ENSG00000105281, ENSG00000165349",Blue Earth,Radioactive diagnostic,Other,Other indication,Suspected prostate cancer recurrence,prostate cancer,MONDO_0008315,P,2016,TRUE,,Severe
Ayvakit,Avapritinib,AVAPRITINIB,CHEMBL4204794,"ENSG00000157404, ENSG00000134853",Blueprint Medicines,"PDGFRA, PDGFRA mutants and KIT kinase inhibitor",Oncology,Oncology,GIST with PDGFRA exon 18 mutations,gastrointestinal stromal tumor,MONDO_0011719,"P, O, B, F",2020,TRUE,,Severe
Azstarys,Dexmethylphenidate; serdexmethylphenidate,Dexmethylphenidate; serdexmethylphenidate,CHEMBL827; CHEMBL4301162,"ENSG00000103546, ENSG00000142319; ENSG00000142319, ENSG00000103546",Commave Therapeutics,CNS stimulant,Other,Other indication,ADHD,attention deficit hyperactivity disorder,EFO_0003888,S,2021,TRUE,,Non Severe
Balversa,Erdafitinib,ERDAFITINIB,CHEMBL3545376,"ENSG00000077782, ENSG00000066468, ENSG00000160867, ENSG00000068078",Janssen /J&J,FGFR inhibitor,Oncology,Oncology,Bladder cancer,urinary bladder carcinoma,MONDO_0004986,"P, B, A",2019,TRUE,,Severe
Barhemsys,Amisulpride,AMISULPRIDE,CHEMBL243712,"ENSG00000151577, ENSG00000149295, ENSG00000164270, ENSG00000157219, ENSG00000158748, ENSG00000166736, ENSG00000186090, ENSG00000178084, ENSG00000102468, ENSG00000149305, ENSG00000179097, ENSG00000135914, ENSG00000178394, ENSG00000168830, ENSG00000147246, ENSG00000186038, ENSG00000148680, ENSG00000135312, ENSG00000179546",Acacia,Dopamine receptors D2 & D3 antagonist,Other,Other indication,Nausea and vomiting after surgery,Nausea and vomiting,HP_0002017,S,2020,FALSE,Symptomatic,Non Severe
Bavencio,Avelumab,AVELUMAB,CHEMBL3833373,ENSG00000120217,Merck KGaA/Pfizer,PDL1-blocking antibody,Oncology,Oncology,Merkel cell carcinoma,Merkel cell skin cancer,EFO_1001471,"P, O, B, A, F",2017,TRUE,,Severe
Baxdela,Delafloxacin,DELAFLOXACIN,CHEMBL2105637,NA,Melinta Therapeutics,Fluoroquinolone antibacterial,Other,No human target,Acute bacterial skin and skin structure infections,staphylococcal skin infections,EFO_1001849,"P, F",2017,NA,,Non Severe
Beleodaq,Belinostat,BELINOSTAT,CHEMBL408513,"ENSG00000108840, ENSG00000147099, ENSG00000061273, ENSG00000068024, ENSG00000171720, ENSG00000094631, ENSG00000163517, ENSG00000048052, ENSG00000100429, ENSG00000196591, ENSG00000116478",Spectrum,Histone-deacetylase inhibitor,Oncology,Other indication,Peripheral T-cell lymphoma,unspecified peripheral T-cell lymphoma,EFO_0000211,"P, O, A, F",2014,TRUE,,Severe
Belsomra,Suvorexant,SUVOREXANT,CHEMBL1083659,"ENSG00000137252, ENSG00000121764",Merck & Co.,Orexin-receptor antagonist,Other,Other indication,Insomnia,insomnia,EFO_0004698,S,2014,TRUE,,Non Severe
Benznidazole,Benznidazole,BENZNIDAZOLE,CHEMBL110,NA,Chemo Research,Nitroimidazole antimicrobial,Other,No human target,Chagas disease,Chagas disease,MONDO_0001444,"P, O, A",2017,NA,,Severe
Beovu,Brolucizumab,BROLUCIZUMAB,CHEMBL3707357,ENSG00000112715,Novartis,VEGF inhibitor,Other,Other indication,Wet age-related macular degeneration,macular degeneration,EFO_0009606,S,2019,TRUE,,Not concordant
Besponsa,Inotuzumab ozogamicin,INOTUZUMAB OZOGAMICIN,CHEMBL2108611,ENSG00000012124,Pfizer,CD22-directed antibody‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚àö√´‚Äö√†√∂¬¨¬Ædrug conjugate,Oncology,Oncology,B cell precursor ALL,precursor B-cell acute lymphoblastic leukemia,MONDO_0020511,"P, O, B",2017,TRUE,,Severe
Besremi,Ropeginterferon alfa-2b,Ropeginterferon alfa-2b,CHEMBL4297819,"ENSG00000142166, ENSG00000159110",Pharmaessentia,PEGylated interferon alpha-2b,Oncology,Oncology,Polycythaemia vera,polycythemia vera,EFO_0002429,"S, O",2021,TRUE,,Severe
Bevyxxa,Betrixaban,BETRIXABAN,CHEMBL512351,ENSG00000126218,Portola Pharmaceuticals,FXa inhibitor,Other,Other indication,Prophylaxis of venous thromboembolism,venous thromboembolism,EFO_0004286,"P, F",2017,TRUE,,Severe
Biktarvy,Bictegravir; emtricitabine; tenofovir alafenamide,BICTEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE,CHEMBL3989866; CHEMBL885; CHEMBL2107825,NA; NA; NA,Gilead Sciences,HIV-1 integrase inhibitor and HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors,Other,No human target,HIV,hiv infection,EFO_0000764,P,2018,NA,,Severe
Blenrep,Belantamab mafodotin,BELANTAMAB MAFODOTIN,CHEMBL4298209,"ENSG00000048462, ENSG00000152086, ENSG00000167553, ENSG00000188229, ENSG00000137267, ENSG00000176014, ENSG00000261456, ENSG00000127824, ENSG00000123416, ENSG00000137285, ENSG00000258947, ENSG00000167552, ENSG00000198033, ENSG00000196230, ENSG00000104833, ENSG00000101162",GlaxoSmithKline,"BCMA-directed ADC, with microtubule inhibitor",Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O, B, A",2020,TRUE,,Severe
Blincyto,Blinatumomab,BLINATUMOMAB,CHEMBL1742992,"ENSG00000177455, ENSG00000160654, ENSG00000167286, ENSG00000198851",Amgen,CD19- and CD3-bispecific antibody,Oncology,Oncology,B-ALL,precursor B-cell acute lymphoblastic leukemia,MONDO_0020511,"P, O, B, A",2014,TRUE,,Severe
Braftovi,Encorafenib,ENCORAFENIB,CHEMBL3301612,ENSG00000157764,Array BioPharma,BRAF inhibitor,Oncology,Oncology,BRAF-mutated melanoma,melanoma,EFO_0000756,"S, O",2018,TRUE,,Severe
Breo Ellipta,Fluticasone; vilanterol,FLUTICASONE; VILANTEROL,CHEMBL1473; CHEMBL1198857,ENSG00000113580; ENSG00000169252,GSK,Corticosteroid plus LABA,Other,Other indication,Chronic obstructive pulmonary disease,chronic obstructive pulmonary disease,EFO_0000341,S,2013,TRUE,,Severe
Brexafemme,Ibrexafungerp,Ibrexafungerp,CHEMBL4297513,NA,Scynexis,Triterpenoid antifungal,Other,No human target,Vulvovaginal candidiasis,NA,NA,"P, F",2021,NA,,NA
Bridion,Sugammadex,SUGAMMADEX,CHEMBL2111107,NA,Merck & Co.,A modified gamma cyclodextrin,Other,No human target,Reversal of neuromuscular blockade during surgery,neuromuscular disease,EFO_1001902,P,2015,NA,,Severe
Brineura,Cerliponase alfa,CERLIPONASE ALFA,CHEMBL3544921,ENSG00000166340,BioMarin Pharmaceutical,Tripeptidyl peptidase,Other,Other indication,Tripeptidyl peptidase 1 deficiency (neuronal ceroid lipofuscinosis type 2*),neuronal ceroid lipofuscinosis 2,MONDO_0008769,"P, O, B",2017,TRUE,,Severe
Brintellix,Vortioxetine,VORTIOXETINE,CHEMBL2104993,"ENSG00000178394, ENSG00000108576, ENSG00000166736",Takeda,Serotonin reuptake inhibitor,Other,Other indication,Major depressive disorder,major depressive disorder,MONDO_0002009,S,2013,TRUE,,Non Severe
Briumvi,Ublituximab,Ublituximab,CHEMBL2108354,ENSG00000156738,TG Therapeutics,CD20-targeted mAb,Other,Other indication,Relapsing forms of multiple sclerosis,relapsing-remitting multiple sclerosis,EFO_0003929,S,2022,FALSE,,Severe
Briviact,Brivaracetam,BRIVARACETAM,CHEMBL607400,"ENSG00000159164, ENSG00000144285",UCB,"Anticonvulsant with unknown MOA, binds to SV2A",Other,Other indication,Partial-onset seizures,Focal-onset seizure,HP_0007359,S,2016,TRUE,,Not concordant
Brukinsa,Zanubrutinib,ZANUBRUTINIB,CHEMBL3936761,ENSG00000010671,BeiGene,BTK inhibitor,Oncology,Oncology,Mantle cell lymphoma,mantle cell lymphoma,EFO_1001469,"P, O, B, A, F",2019,TRUE,,Severe
Byfavo,Remimazolam,REMIMAZOLAM,CHEMBL4297526,"ENSG00000102287, ENSG00000163288, ENSG00000186297, ENSG00000145864, ENSG00000113327, ENSG00000011677, ENSG00000094755, ENSG00000163285, ENSG00000151834, ENSG00000109158, ENSG00000268089, ENSG00000187730, ENSG00000182256, ENSG00000022355, ENSG00000145863, ENSG00000166206",Acacia,Benzodiazepine,Other,Other indication,Procedural sedation,sedation,EFO_0009868,S,2020,TRUE,,Non Severe
Bylvay,Odevixibat,Odevixibat,CHEMBL4297588,ENSG00000125255,Albireo,IBAT inhibitor,Other,Other indication,Pruritus in PFIC,familial intrahepatic cholestasis,MONDO_0017290,"P, O, F",2021,TRUE,,Severe
Cabenuva Kit,Cabotegravir; rilpivirine,Cabotegravir; rilpivirine,CHEMBL2403238; CHEMBL175691,NA; NA,ViiV,INSTI and an NNRTI,Other,No human target,HIV-1 infection,NA,NA,"P, F",2021,NA,,NA
Cablivi,Caplacizumab,CAPLACIZUMAB,CHEMBL2109624,ENSG00000110799,Sanofi/Ablynx,vWF-directed nanobody,Other,Other indication,ATTP,thrombotic thrombocytopenic purpura,MONDO_0018896,"P, O, F",2019,TRUE,,Severe
Calquence,Acalabrutinib,ACALABRUTINIB,CHEMBL3707348,ENSG00000010671,AstraZeneca/Acerta Pharma,BTK inhibitor,Oncology,Oncology,Mantle cell lymphoma,Mantle cell lymphoma,EFO_1001469,"P, O, B, A",2017,TRUE,,Severe
Camzyos,Mavacamten,Mavacamten,CHEMBL4297517,ENSG00000092054,Bristol Myers Squibb,Cardiac myosin inhibitor,Other,Other indication,Classes of obstructive HCM (Hypertrophic Obstructive Cardiomyopathy),hypertrophic cardiomyopathy,EFO_0000538,"S, O, B",2022,TRUE,,Severe
Caplyta,Lumateperone,LUMATEPERONE,CHEMBL3306803,"ENSG00000102468, ENSG00000108576, ENSG00000149295",Intra-Cellular Therapies,Atypical antipsychotic,Other,Other indication,Schizophrenia,schizophrenia,MONDO_0005090,"S, F",2019,TRUE,,Not concordant
Cerdelga,Eliglustat,ELIGLUSTAT,CHEMBL2110588,ENSG00000148154,Genzyme,Glucosylceramide-synthase inhibitor,Other,Other indication,Gaucher's disease,Gaucher disease,MONDO_0018150,"P, O",2014,FALSE,,Severe
Cholbam,Cholic acid,CHOLIC ACID,CHEMBL205596,NA,Retrophin,A primary bile acid,Other,No human target,Bile acid synthesis disorders and peroxisomal disorders,peroxisomal disease; Disorder of bile acid synthesis,MONDO_0019053; Orphanet_79168,"P, O",2015,NA,,Severe
Cibinqo,Abrocitinib,Abrocitinib,CHEMBL3655081,ENSG00000162434,Pfizer,JAK inhibitor,Other,Other indication,Atopic dermatitis,"atopic eczema, Eczema",EFO_0000274; HP_0000964,"P, B",2022,TRUE,,Non Severe
Cinqair,Reslizumab,RESLIZUMAB,CHEMBL2107884,ENSG00000113525,Teva,IL-5 antagonist,Other,Other indication,Severe asthma,Status Asthmaticus,EFO_0008590,S,2016,TRUE,,Severe
Copiktra,Duvelisib,DUVELISIB,CHEMBL3039502,"ENSG00000105851, ENSG00000171608",Verastem,PI3K inhibitor,Oncology,Oncology,"CLL, FL and SLL",chronic lymphocytic leukemia; follicular lymphoma,EFO_0000095; MONDO_0018906,"P, O, A, F",2018,TRUE,,Severe
Copper dotatate Cu-64,Copper dotatate Cu-64,COPPER DOTATATE CU-64,CHEMBL4297339,ENSG00000180616,Radiomedix,Radioactive diagnostic,Other,Other indication,"Imaging, cancer",neuroendocrine neoplasm,EFO_1001901,"P, O, F",2020,TRUE,Imaging,Severe
Corlanor,Ivabradine,IVABRADINE,CHEMBL471737,ENSG00000138622,Amgen,Hyperpolarization-activated cyclic nucleotide-gated channel blocker,Other,Other indication,Chronic heart failure,congestive heart failure,EFO_0000373,"P, F",2015,TRUE,,Severe
Cosela,Trilaciclib,Trilaciclib,CHEMBL3894860,"ENSG00000135446, ENSG00000105810",G1 Therapeutics,CDK4 and CDK6 kinase inhibitor,Oncology,Oncology,Chemotherapy-induced myelosuppression,myelosuppression; small cell lung carcinoma,EFO_0007053; EFO_0000702,"P, B",2021,TRUE,,Severe
Cosentyx,Secukinumab,SECUKINUMAB,CHEMBL1743068,ENSG00000112115,Novartis,IL-17A antagonist,Other,Other indication,"Plaque psoriasis, *psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.",psoriasis vulgaris,EFO_1001494,S,2015,FALSE,,Non severe
Cotellic,Cobimetinib,COBIMETINIB,CHEMBL2146883,"ENSG00000126934, ENSG00000169032",Genentech,MEK inhibitor,Oncology,Oncology,Melanoma with BRAFV600E/K mutations,melanoma,EFO_0000756,"P, O, F",2015,TRUE,,Severe
Cresemba,Isavuconazonium,ISAVUCONAZONIUM,CHEMBL1183349,NA,Astellas,Azole antifungal,Other,No human target,Antifungal,aspergillosis; mucormycosis,EFO_0007157; EFO_0007380,"P, O",2015,NA,,Severe
Crysvita,Burosumab,BUROSUMAB,CHEMBL3707326,ENSG00000118972,Ultragenyx Pharmaceutical/Kyowa Hakko Kirin,FGF23 antibody,Other,Other indication,X-linked hypophosphataemia,Hypophosphatemia,HP_0002148,"P, O, B, F",2018,TRUE,,Non Severe
Cyramza,Ramucirumab,RAMUCIRUMAB,CHEMBL1743062,ENSG00000128052,Eli Lilly,VEGFR2 antagonist,Oncology,Oncology,Gastric cancer,gastric cancer,MONDO_0001056,"P, O, F",2014,TRUE,,Severe
Cytalux,Pafolacianine,Pafolacianine,CHEMBL4297412,ENSG00000110195,On Target Labs,Fluorescent FR imaging agent,Other,Other indication,Ovarian cancer imaging,ovarian carcinoma,EFO_0001075,"P, O, F",2021,FALSE,Imaging,Severe
Daklinza,Daclatasvir,DACLATASVIR,CHEMBL2023898,NA,Bristol-Myers Squibb,NS5A inhibitor,Other,No human target,HCV,hepatitis C virus infection,EFO_0003047,"P, F",2015,NA,,Severe
Dalvance,Dalbavancin,DALBAVANCIN,CHEMBL3301669,NA,Durata,Semisynthetic lipoglycopeptide,Other,No human target,ABSSSI (Acute Bacterial Skin and Skin Structure Infections),staphylococcal skin infections,EFO_1001849,"P, F",2014,NA,,Non Severe
Danyelza,Naxitamab,NAXITAMAB,CHEMBL4297984,NA,Y-mAbs Therapeutics,GD2-directed mAb,Oncology,,High-risk neuroblastoma,neuroblastoma,EFO_0000621,"P, O, B, A",2020,NA,,Severe
Darzalex,Daratumumab,DARATUMUMAB,CHEMBL1743007,ENSG00000004468,Johnson & Johnson,CD38-directed mAb,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O, B, A, F",2015,TRUE,,Severe
Daurismo,Glasdegib,GLASDEGIB,CHEMBL2043437,ENSG00000128602,Pfizer,Hedgehog pathway inhibitor,Oncology,Oncology,AML,acute myeloid leukemia,EFO_0000222,"P, O",2018,TRUE,,Severe
Daxxify,DaxibotulinumtoxinA,DaxibotulinumtoxinA,CHEMBL3707359,ENSG00000132639,Revance,Botulinum toxin,Other,Other indication,Glabellar lines,Facial wrinkling,HP_0009762,S,2022,FALSE,Symptomatic,Non severe
Dayvigo,Lemborexant,LEMBOREXANT,CHEMBL3545367,"ENSG00000121764, ENSG00000137252",Eisai,Orexin receptor antagonist,Other,Other indication,Insomnia,insomnia,EFO_0004698,S,2019,TRUE,,Non Severe
Defitelio,Defibrotide sodium,DEFIBROTIDE SODIUM,CHEMBL3707226,ENSG00000122194,Gentium,Profibrinolytic,Other,Other indication,Hepatic veno-occlusive disease,hepatic veno-occlusive disease,MONDO_0019514,"P, O, F",2016,TRUE,,Severe
Diacomit,Stiripentol,STIRIPENTOL,CHEMBL1983350,ENSG00000022355,Biocodex,GABA reuptake inhibitor,Other,Other indication,Dravet syndrome,dravet syndrome,Orphanet_33069,"P, O",2018,TRUE,,Severe
Dojolvi,Triheptanoin,TRIHEPTANOIN,CHEMBL4297585,NA,Ultragenyx,Medium-chain triglyceride,Other,No human target,LC-FAODs,inherited fatty acid metabolism disorder,MONDO_0037858,"S, O, F",2020,NA,,Severe
Doptelet,Avatrombopag,AVATROMBOPAG,CHEMBL2103883,ENSG00000117400,Dova Pharmaceuticals,Thrombopoietin receptor agonist,Other,Other indication,Thrombocytopenia,thrombocytopenia,HP_0001873,P,2018,TRUE,,Not concordant
Dotarem,Gadoterate meglumine,GADOTERATE MEGLUMINE,CHEMBL2219415,NA,Guerbet,Gadolinium-based contrast agent,Other,No human target,Contrast agent to visualize disruption of the blood-brain barrier,NA,NA,P,2013,NA,,NA
Duavee,Bazedoxifene acetate; oestrogens,"BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED",CHEMBL2106615; CHEMBL1201649,"ENSG00000091831, ENSG00000140009; ENSG00000140009, ENSG00000091831",Pfizer,Conjugated oestrogens with an oestrogen receptor modulator,Other,Other indication,Moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis,menopause; postmenopausal osteoporosis,EFO_0003922; EFO_0003854,S,2013,TRUE,,Non severe
Dupixent,Dupilumab,DUPILUMAB,CHEMBL2108675,ENSG00000077238,Regeneron/Sanofi,IL-4Ralpha antagonist,Other,Other indication,Atopic dermatitis,atopic eczema,EFO_0000274,"P, B",2017,TRUE,,Non Severe
Ebanga,Ansuvimab,ANSUVIMAB,CHEMBL4594388,NA,Ridgeback,Ebola glycoprotein-directed mAb,Other,No human target,Ebola virus,Ebola hemorrhagic fever,EFO_0007243,"P, O, B",2020,NA,,Severe
Egaten,Triclabendazole,TRICLABENDAZOLE,CHEMBL1086440,NA,Novartis,Anthelmintic,Other,No human target,Fascioliasis,fascioliasis,EFO_1001324,"P, O, F",2019,NA,,Not concordant
Elahere,Mirvetuximab soravtansine,Mirvetuximab soravtansine,CHEMBL3545132,"ENSG00000110195, ENSG00000127824, ENSG00000152086, ENSG00000261456, ENSG00000101162, ENSG00000188229, ENSG00000104833, ENSG00000258947, ENSG00000123416, ENSG00000198033, ENSG00000167553, ENSG00000137285, ENSG00000167552, ENSG00000176014, ENSG00000137267, ENSG00000196230",ImmunoGen,FR_-targeted antibody-drug conjugate,Oncology,Oncology,Ovarian cancer,ovarian carcinoma,EFO_0001075,"P, O, A, F",2022,TRUE,,Severe
Elucirem,Gadopiclenol,Gadopiclenol,CHEMBL4297634,NA,Guerbet,Gadolinium-based contrast agent,Other,No human target,Lesions with abnormal vascularity,NA,NA,P,2022,NA,,NA
Elzonris,Tagraxofusp,TAGRAXOFUSP,CHEMBL4297573,"ENSG00000167658, ENSG00000185291",Stemline Therapeutics,IL-3 and diphtheria toxin fusion protein,Oncology,Oncology,Blastic plasmacytoid dendritic cell neoplasm,blastic plasmacytoid dendritic cell neoplasm,EFO_0010580,"P, O, B",2018,FALSE,,Severe
Emflaza,Deflazacort,DEFLAZACORT,CHEMBL1201891,ENSG00000113580,PTC Therapeutics,Corticosteroid,Other,Other indication,Duchenne muscular dystrophy,Duchenne muscular dystrophy,MONDO_0010679,"P, O, F",2017,FALSE,Symptomatic,Severe
Emgality,Galcanezumab,GALCANEZUMAB,CHEMBL3707328,"ENSG00000175868, ENSG00000110680",Eli Lilly,CGRP antibody,Other,Other indication,Migraine,migraine disorder,MONDO_0005277,"S, F",2018,TRUE,,Non Severe
Empaveli,Pegcetacoplan,Pegcetacoplan,CHEMBL4298211,ENSG00000125730,Apellis,Complement protein C3 inhibitor,Other,Other indication,PNH,paroxysmal nocturnal hemoglobinuria,MONDO_0100244,"P, O, F",2021,TRUE,,Severe
Empliciti,Elotuzumab,ELOTUZUMAB,CHEMBL1743010,ENSG00000026751,Bristol-Myers Squibb,SLAMF7-directed mAb,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O, B",2015,TRUE,,Severe
Enhertu,Trastuzumab deruxtecan,TRASTUZUMAB DERUXTECAN,CHEMBL4297844,"ENSG00000141736, ENSG00000198900",Daiichi Sankyo/AstraZeneca,HER2-directed ADC,Oncology,Oncology,HER2-positive breast cancer,HER2 Positive Breast Carcinoma,EFO_1000294,"P, B, A, F",2019,TRUE,,Severe
Enjaymo,Sutimlimab,Sutimlimab,CHEMBL4297832,ENSG00000182326,Bioverativ,C1s-targeted mAb,Other,Other indication,RBC transfusion due to haemolysis in CAD (cold agglutinin disease),"Anemia, Hemolytic, Autoimmune",EFO_1001264,"P, O, B",2022,FALSE,Symptomatic,Severe
Enspryng,Satralizumab,SATRALIZUMAB,CHEMBL3833307,"ENSG00000160712, ENSG00000134352",Roche/Genentech,IL-6R-directed mAb,Other,Other indication,NMOSD,neuromyelitis optica,EFO_0004256,"S, O, B, F",2020,TRUE,,Severe
Entresto,Sacubitril; valsartan,SACUBITRIL; VALSARTAN,CHEMBL3137301; CHEMBL1069,ENSG00000196549; ENSG00000144891,Novartis,A neprilysin inhibitor plus an angiotensin II receptor blocker,Other,Other indication,Chronic heart failure,congestive heart failure,EFO_0000373,"P, F",2015,TRUE,,Severe
Entyvio,Vedolizumab,VEDOLIZUMAB,CHEMBL1743087,"ENSG00000115232, ENSG00000139626",Takeda,Integrin-receptor antagonist,Other,Other indication,Ulcerative colitis and Crohn's disease,ulcerative colitis; Crohn's disease,EFO_0000729; EFO_0000384,"P, F",2014,TRUE,,Severe
Epclusa,Sofosbuvir; velpatasvir,SOFOSBUVIR; VELPATASVIR,CHEMBL1259059; CHEMBL3545062,NA; NA,Gilead Sciences,A nucleotide analogue NS5B polymerase inhibitor plus an HCV NS5A inhibitor,Other,No human target,"genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV)",hepatitis C virus infection,EFO_0003047,"P, B, F",2016,NA,,Severe
Epidiolex,Cannabidiol,CANNABIDIOL,CHEMBL190461,ENSG00000118432,GW Pharmaceuticals,Cannabinoid,Other,Other indication,Dravet syndrome and Lennox-Gastaut syndrome,Dravet syndrome; Lennox-Gastaut syndrome,Orphanet_33069; MONDO_0016532,"P, O, F",2018,TRUE,,Severe
Erleada,Apalutamide,APALUTAMIDE,CHEMBL3183409,ENSG00000169083,Johnson & Johnson,Androgen receptor inhibitor,Oncology,Oncology,Prostate cancer,prostate cancer,MONDO_0008315,"P, F",2018,TRUE,,Severe
Esbriet,Pirfenidone,PIRFENIDONE,CHEMBL1256391,NA,InterMune,MOA unknown,Other,No human target,IPF (idiopathic pulmonary fibrosis),idiopathic pulmonary fibrosis,EFO_0000768,"P, O, B, F",2014,NA,,Severe
Eucrisa,Crisaborole,CRISABOROLE,CHEMBL484785,"ENSG00000184588, ENSG00000113448, ENSG00000065989, ENSG00000105650",Pfizer/Anacor Pharmaceuticals,PDE4 inhibitor,Other,Other indication,Atopic dermatitis,atopic eczema,EFO_0000274,S,2016,TRUE,,Non Severe
Evenity,Romosozumab,ROMOSOZUMAB,CHEMBL2107874,ENSG00000167941,Amgen,Sclerostin inhibitor,Other,Other indication,Osteoporosis,osteoporosis,EFO_0003882,S,2019,TRUE,,Non severe
Evkeeza,Evinacumab,Evinacumab,CHEMBL3545191,ENSG00000132855,Regeneron,ANGPTL3-targeted mAb,Other,Other indication,HoFH,homozygous familial hypercholesterolemia,MONDO_0018328,"P, O, B",2021,TRUE,,Severe
Evrysdi,Risdiplam,RISDIPLAM,CHEMBL4297528,ENSG00000205571,Roche/Genentech,SMN2 splicing modifier,Other,Other indication,Spinal muscular atrophy,spinal muscular atrophy,EFO_0008525,"P, O, F",2020,TRUE,,Severe
ExEm Foam,Air polymer-type A,AIR POLYMER-TYPE A,CHEMBL4594264,NA,Giskit,Ultrasound contrast agent,Other,No human target,Assess fallopian tube patency in women with known or suspected infertility,infertility,EFO_0000545,S,2019,NA,,Non Severe
Exkivity,Mobocertinib,Mobocertinib,CHEMBL4650319,ENSG00000146648,Takeda,EGFR kinase inhibitor,Oncology,Oncology,EGFR exon 20-mutated NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A, F",2021,TRUE,,Severe
Exondys 51,Eteplirsen,ETEPLIRSEN,CHEMBL2108278,ENSG00000198947,Sarepta Therapeutics,ASO designed to target dystrophin pre-mRNA,Other,Other indication,Duchenne muscular dystrophy,Duchenne muscular dystrophy,MONDO_0010679,"P, O, A, F",2016,TRUE,,Severe
Farxiga,Dapagliflozin,DAPAGLIFLOZIN,CHEMBL429910,ENSG00000140675,AstraZeneca,SGLT2 inhibitor,Other,Other indication,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,"S, F",2014,TRUE,,Non Severe
Farydak,Panobinostat,PANOBINOSTAT,CHEMBL483254,"ENSG00000100429, ENSG00000196591, ENSG00000163517, ENSG00000061273, ENSG00000068024, ENSG00000048052, ENSG00000116478, ENSG00000108840, ENSG00000094631, ENSG00000171720, ENSG00000147099",Novartis,Histone deacetylase inhibitor,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O, A",2015,TRUE,,Severe
Fasenra,Benralizumab,BENRALIZUMAB,CHEMBL1742991,ENSG00000091181,AstraZeneca,IL-5Ralpha-directed monoclonal antibody,Other,Other indication,Severe asthma,Status Asthmaticus,EFO_0008590,S,2017,FALSE,,Severe
Fetroja,Cefiderocol,CEFIDEROCOL,CHEMBL3989974,NA,Shionogi,Cephalosporin antibacterial,Other,No human target,Complicated urinary tract infections,urinary tract infection,EFO_0003103,"P, F",2019,NA,,Non Severe
Fexinidazole,Fexinidazole,Fexinidazole,CHEMBL1631694,NA,Sanofi/DNDi,Nitroimidazole antimicrobial,Other,No human target,Sleeping sickness,NA,NA,"P, O",2021,NA,,NA
Firdapse,Amifampridine,AMIFAMPRIDINE,CHEMBL354077,"ENSG00000130037, ENSG00000182255, ENSG00000173826, ENSG00000111262, ENSG00000178342, ENSG00000131398, ENSG00000140015, ENSG00000055118, ENSG00000168418, ENSG00000143473, ENSG00000183960, ENSG00000151079, ENSG00000184408, ENSG00000116396, ENSG00000171126, ENSG00000168263, ENSG00000026559, ENSG00000170745, ENSG00000185760, ENSG00000135519, ENSG00000184156, ENSG00000075043, ENSG00000117013, ENSG00000158445, ENSG00000166006, ENSG00000129159, ENSG00000124134, ENSG00000156486, ENSG00000143105, ENSG00000182674, ENSG00000053918, ENSG00000089558, ENSG00000177301, ENSG00000162975, ENSG00000102057, ENSG00000184611, ENSG00000171385, ENSG00000177272, ENSG00000104848, ENSG00000164794",Catalyst Pharmaceuticals,Potassium channel blocker,Other,Other indication,Lambert-Eaton myasthenic syndrome,Lambert-Eaton myasthenic syndrome,Orphanet_43393,"P, O",2018,FALSE,Symptomatic,Severe
Flortaucipir F-18,Flortaucipir F-18,FLORTAUCIPIR F-18,CHEMBL3545253,ENSG00000186868,Eli Lilly,Radioactive diagnostic,Other,Other indication,"Imaging, tau in Alzheimer disease",Alzheimer disease,MONDO_0004975,P,2020,TRUE,Imaging,Severe
Fluorodopa F-18,Fluorodopa F-18,FLUORODOPA F-18,CHEMBL3400972,NA,Feinstein Institutes,Radioactive diagnostic,Other,No human target,Diagnosis of parkinsonian syndromes,Parkinson disease,MONDO_0005180,S,2019,NA,,Severe
Fluoroestradiol F-18,Fluoroestradiol F-18,FLUOROESTRADIOL F-18,CHEMBL4594261,ENSG00000186868,Zionexa,Radioactive diagnostic,Other,Other indication,"Imaging, breast cancer",breast carcinoma,EFO_0000305,S,2020,TRUE,Imaging,Severe
Fotivda,Tivozanib,Tivozanib,CHEMBL1289494,"ENSG00000102755, ENSG00000128052, ENSG00000037280, ENSG00000157404, ENSG00000113721",Aveo,VEGFR kinase inhibitor,Oncology,Oncology,Renal cell carcinoma,renal cell carcinoma,EFO_0000681,S,2021,TRUE,,Severe
Galafold,Migalastat,MIGALASTAT,CHEMBL110458,ENSG00000102393,Amicus Therapeutics,beta-galactosidase regulator,Other,Other indication,Fabry disease,fabry disease,MONDO_0010526,"P, O, A, F",2018,TRUE,,Severe
Gallium dotatoc Ga-68,Gallium dotatoc Ga-68,GALLIUM DOTATOC GA-68,CHEMBL4297340,ENSG00000180616,UIHC PET Imaging Center,Radioactive diagnostic,Other,Other indication,Localization of somatostatin receptor-positive neuroendocrine tumours,neuroendocrine neoplasm,EFO_1001901,"S, O",2019,TRUE,,Severe
Gamifant,Emapalumab,EMAPALUMAB,CHEMBL3989977,ENSG00000111537,Novimmune,Interferon-‚Äö√¢√†‚àö‚â†‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢-blocking antibody,Other,Other indication,Primary haemophagocytic lymphohistiocytosis,genetic hemophagocytic lymphohistiocytosis,MONDO_0015541,"P, O, B",2018,TRUE,,Severe
Gavreto,Pralsetinib,PRALSETINIB,CHEMBL4582651,"ENSG00000170759, ENSG00000165731, ENSG00000108091",Blueprint Medicines/Roche,RET kinase inhibitor,Oncology,Oncology,RET fusion-positive NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A",2020,TRUE,,Severe
Gazyva,Obinutuzumab,OBINUTUZUMAB,CHEMBL1743048,ENSG00000156738,Genentech,Humanized CD20-specific monoclonal antibody,Oncology,Oncology,Previously untreated chronic lymphocytic leukaemia,chronic lymphocytic leukemia,EFO_0000095,"P, O, B",2013,TRUE,,Severe
Gemtesa,Vibegron,VIBEGRON,CHEMBL2107826,ENSG00000188778,Urovant Sciences,Beta-3 adrenergic receptor agonist,Other,Other indication,Overactive bladder,overactive bladder,EFO_1000781,S,2020,FALSE,Symptomatic,Non Severe
Genvoya,Elvitegravir; cobicistat; emtricitabine; tenofovir,ELVITEGRAVIR; COBICISTAT; EMTRICITABINE; TENOFOVIR,CHEMBL204656; CHEMBL2095208; CHEMBL885; CHEMBL483,"NA; ENSG00000160870, ENSG00000106258, ENSG00000160868, ENSG00000021461; NA; NA",Gilead,An INSTI plus a CYP3A inhibitor plus two nucleoside analogue reverse transcriptase inhibitors,Other,No human target,HIV,HIV infection,EFO_0000764,"S, F",2015,NA,,Severe
Giapreza,Angiotensin II,ANGIOTENSIN II,CHEMBL408403,ENSG00000144891,La Jolla Pharmaceutical Company,Synthetic human angiotensin,Other,Other indication,Blood pressure in adults with septic or other distributive shock,septic shock; blood pressure,EFO_0006834; EFO_0004325,P,2017,TRUE,,Severe
Gilotrif,Afatinib,AFATINIB,CHEMBL1173655,"ENSG00000141736, ENSG00000146648, ENSG00000178568",Boehringer Ingelheim,"EGFR (ERBB1), HER2 (ERBB2), and HER4 (ERRB4) kinase inhibitor",Oncology,Oncology,First-line treatment of patients with metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test,non-small cell lung carcinoma,EFO_0003060,"P, O, F",2013,TRUE,,Severe
Givlaari,Givosiran,GIVOSIRAN,CHEMBL4297760,ENSG00000023330,Alnylam,ALAS1-directed siRNA,Other,Other indication,Acute hepatic porphyria,acute hepatic porphyria,Orphanet_95157,"P, O, B",2019,FALSE,,Severe
Harvoni,Ledipasvir; sofosbuvir,LEDIPASVIR; SOFOSBUVIR,CHEMBL2374220; CHEMBL1259059,NA; NA,Gilead Sciences,An NS5A inhibitor plus an HCV nucleotide-analogue NS5B-polymerase inhibitor,Other,No human target,Genotype 1 HCV,hepatitis C virus infection,EFO_0003047,"P, B, F",2014,NA,,Severe
Hemlibra,Emicizumab,EMICIZUMAB,CHEMBL3833393,"ENSG00000126218, ENSG00000101981",Roche/Genentech,Bispecific FIX and FX-directed antibody,Other,Other indication,Haemophilia A,hemophilia A,MONDO_0010602,"P, O, B",2017,TRUE,,Severe
Hetlioz,Tasimelteon,TASIMELTEON,CHEMBL2103822,"ENSG00000134640, ENSG00000168412",Vanda,Melatonin-receptor agonist,Other,Other indication,Non-24-hour sleep-wake disorder,sleep-wake disorder,MONDO_0003406,"P, O",2014,TRUE,,Non Severe
Ibrance,Palbociclib,PALBOCICLIB,CHEMBL189963,"ENSG00000135446, ENSG00000110092, ENSG00000105810",Pfizer,CDK4 and CDK6 inhibitor,Oncology,Oncology,"ER-positive, HER2-negative advanced breast cancer",HER2 negative breast carcinoma,EFO_0009780,"P, B, A",2015,TRUE,,Severe
Ibsrela,Tenapanor,TENAPANOR,CHEMBL3304485,ENSG00000066230,Ardelyx,NHE3 inhibitor,Other,Other indication,IBS with constipation,irritable bowel syndrome,EFO_0000555,S,2019,FALSE,,Non severe
Idhifa,Enasidenib mesylate,ENASIDENIB MESYLATE,CHEMBL3989931,ENSG00000182054,Celgene/Agios,IDH2 inhibitor,Oncology,Oncology,IDH2-mutated AML,acute myeloid leukemia,EFO_0000222,"P, O, F",2017,TRUE,,Severe
Ilumya,Tildrakizumab,TILDRAKIZUMAB,CHEMBL2108681,"ENSG00000110944, ENSG00000113302",Sun Pharma,IL-23 antibody,Other,Other indication,Plaque psoriasis,psoriasis vulgaris,EFO_1001494,S,2018,TRUE,,Non severe
Imbruvica,Ibrutinib,IBRUTINIB,CHEMBL1873475,ENSG00000010671,Pharmacyclics,Bruton's tyrosine kinase inhibitor,Oncology,Oncology,Mantle cell lymphoma,Mantle cell lymphoma,EFO_1001469,"P, O, B, F",2013,TRUE,,Severe
Imcivree,Setmelanotide,SETMELANOTIDE,CHEMBL3301624,ENSG00000166603,Rhythm,Melanocortin receptor 4 agonist,Other,Other indication,Rare genetic diseases of obesity,Bardet-Biedl syndrome,MONDO_0015229,"P, O, B",2020,TRUE,,Severe
Imfinzi,Durvalumab,DURVALUMAB,CHEMBL3301587,ENSG00000120217,AstraZeneca,PDL1-blocking antibody,Oncology,Oncology,Urothelial carcinoma,urothelial carcinoma,EFO_0008528,"P, B, A",2017,TRUE,,Severe
Imjudo,Tremelimumab,Tremelimumab,CHEMBL2108658,ENSG00000163599,AstraZeneca,CTLA4-targeted mAb,Oncology,Oncology,Hepatocellular carcinoma,hepatocellular carcinoma,EFO_0000182,"S, O",2022,TRUE,,Severe
Impavido,Miltefosine,MILTEFOSINE,CHEMBL125,NA,Knight,MOA unknown,Other,No human target,Leishmaniasis,Leishmaniasis,EFO_0005044,"P, O, F",2014,NA,,Not concordant
Ingrezza,Valbenazine,VALBENAZINE,CHEMBL2364639,ENSG00000165646,Neurocrine Biosciences,VMAT2 inhibitor,Other,Other indication,Tardive dyskinesia,movement disorder,EFO_0004280,"P, B, F",2017,TRUE,,Not concordant
Inmazeb,Atoltivimab; odesivimab; maftivimab,ATOLTIVIMAB; ODESIVIMAB; MAFTIVIMAB,CHEMBL4298183; CHEMBL4298188; CHEMBL4298184,NA; NA; NA,Regeneron,Cocktail of Ebola glycoprotein-directed mAbs,Other,No human target,Ebola virus,Ebola hemorrhagic fever,EFO_0007243,"P, O, B",2020,NA,,Severe
Inqovi,Cedazuridine; decitabine,CEDAZURIDINE; DECITABINE,CHEMBL3237547; CHEMBL1201129,"ENSG00000158825; ENSG00000119772, ENSG00000130816",Otsuka,Cytidine deaminase inhibitor; nucleoside metabolic inhibitor,Other,Other indication,Myelodysplastic syndromes,myelodysplastic syndrome,EFO_0000198,"P, O",2020,TRUE,,Severe
Inrebic,Fedratinib,FEDRATINIB,CHEMBL1287853,"ENSG00000096968, ENSG00000122025",Celgene/BMS,JAK2 and FLT3 inhibitor,Other,Other indication,Myelofibrosis,myelofibrosis,MONDO_0044903,"P, O",2019,TRUE,,Severe
Invokana,Canagliflozin,CANAGLIFLOZIN; CANAGLIFLOZIN,CHEMBL4594217; CHEMBL2048484,ENSG00000140675; ENSG00000140675,Janssen,SGLT2 inhibitor,Other,Other indication,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,S,2013,TRUE,,Non Severe
Isturisa,Osilodrostat,OSILODROSTAT,CHEMBL3099695,ENSG00000160882,Recordati Rare Diseases,Cortisol synthesis inhibitor,Other,Other indication,Cushing disease,Cushing syndrome,EFO_0003099,"S, O",2020,TRUE,,Not concordant
Jardiance,Empagliflozin,EMPAGLIFLOZIN,CHEMBL2107830,ENSG00000140675,Boehringer Ingelheim,SGLT2 inhibitor,Other,Other indication,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,"S, F",2014,TRUE,,Non Severe
Jemperli,Dostarlimab,Dostarlimab,CHEMBL4298124,ENSG00000188389,GlaxoSmithKline,PD1-targeted mAb,Oncology,Oncology,Endometrial cancer,endometrial cancer,MONDO_0011962,"P, B, A",2021,TRUE,,Severe
Jeuveau,Prabotulinumtoxin A,PRABOTULINUMTOXIN A,CHEMBL4297229,ENSG00000132639,Evolus,Acetylcholine release inhibitor and a neuromuscular blocking agent,Other,Other indication,Glabellar lines associated with corrugator and/or procerus muscle activity,Facial wrinkling,HP_0009762,S,2019,FALSE,Symptomatic,Non severe
Jublia,Efinaconazole,EFINACONAZOLE,CHEMBL2103877,NA,Dow,Azole antifungal,Other,No human target,Onychomycosis of the toenails,paronychia,EFO_0007421,S,2014,NA,,Non severe
Kadcyla,Ado-trastuzumab emtansine,TRASTUZUMAB EMTANSINE,CHEMBL1743082,"ENSG00000167553, ENSG00000196230, ENSG00000137285, ENSG00000123416, ENSG00000176014, ENSG00000137267, ENSG00000101162, ENSG00000258947, ENSG00000261456, ENSG00000188229, ENSG00000104833, ENSG00000127824, ENSG00000198033, ENSG00000167552, ENSG00000152086, ENSG00000141736",Genentech,HER2-targeted antibody and microtubule inhibitor conjugate,Oncology,Oncology,HER2-positive metastatic breast cancer,HER2 Positive Breast Carcinoma,EFO_1000294,"P, F",2013,TRUE,,Severe
Kanuma,Sebelipase alfa,SEBELIPASE ALFA,CHEMBL3039537,ENSG00000107798,Alexion,Enzyme replacement therapy,Other,Other indication,LAL deficiency,lysosomal acid lipase deficiency,MONDO_0010204,"P, O, B, F",2015,TRUE,,Severe
Kengreal,Cangrelor,CANGRELOR,CHEMBL334966,ENSG00000169313,Medicines Company,P2Y12 platelet inhibitor,Other,Other indication,"Myocardial infarction, repeat coronary revascularization, and stent thrombosis",myocardial infarction,EFO_0000612,S,2015,FALSE,,Severe
Kerendia,Finerenone,Finerenone,CHEMBL2181927,ENSG00000151623,Bayer,Non-steroidal MR antagonist,Other,Other indication,CKD with type 2 diabetes,chronic kidney disease,EFO_0003884,"P, F",2021,TRUE,,Severe
Kerydin,Tavaborole,TAVABOROLE,CHEMBL443052,NA,Anacor,Oxaborole antifungal,Other,No human target,Onychomycosis of the toenails,paronychia,EFO_0007421,S,2014,NA,,Non severe
Kevzara,Sarilumab,SARILUMAB,CHEMBL2108730,ENSG00000160712,Sanofi/Regeneron,IL-6 receptor antagonist,Other,Other indication,Rheumatoid arthritis,rheumatoid arthritis,EFO_0000685,S,2017,TRUE,,Severe
Keytruda,Pembrolizumab,PEMBROLIZUMAB,CHEMBL3137343,ENSG00000188389,Merck & Co.,PD1-specific antibody,Oncology,Oncology,Metastatic melanoma *and others (2021 approval),metastatic melanoma,EFO_0002617,"P, O, B, A",2014,FALSE,,Severe
Kimmtrak,Tebentafusp,Tebentafusp,CHEMBL4297990,ENSG00000185664,Immunocore,gp100 peptide HLA _ CD3 bispecific T-cell engager,Oncology,Oncology,Uveal melanoma,Uveal Melanoma,EFO_1000616,"P, O, B",2022,FALSE,,Severe
Kisqali,Ribociclib,RIBOCICLIB,CHEMBL3545110,"ENSG00000105810, ENSG00000135446",Novartis,CDK4/6 inhibitor,Oncology,Oncology,"HR-positive, HER2-negative breast cancer",HER2 negative breast carcinoma,EFO_0009780,"P, B",2017,TRUE,,Severe
Klisyri,Tirbanibulin,TIRBANIBULIN,CHEMBL571546,ENSG00000197122,Athenex,Microtubule inhibitor,Other,Other indication,Actinic keratosis,actinic keratosis,EFO_0002496,S,2020,TRUE,,Non severe
Korsuva,Difelikefalin,Difelikefalin,CHEMBL3989915,ENSG00000082556,Cara Therapeutics,kappa-Opioid receptor agonist,Other,Other indication,Pruritus associated with CKD,chronic kidney disease,EFO_0003884,"P, B",2021,FALSE,Symptomatic,Severe
Koselugo,Selumetinib,SELUMETINIB,CHEMBL1614701,"ENSG00000169032, ENSG00000126934",AstraZeneca,MEK1/2 kinase inhibitor,Other,Other indication,Neurofibromatosis type 1,neurofibromatosis type 1,MONDO_0018975,"P, O, B",2020,TRUE,,Severe
Krazati,Adagrasib,Adagrasib,CHEMBL4594350,ENSG00000133703,Mirati,KRAS-G12C inhibitor,Oncology,Oncology,KRASG12C-mutated NSCLC,non-small cell lung carcinoma,EFO_0003060,"S, O, B, A, F",2022,TRUE,,Severe
Krintafel,Tafenoquine,TAFENOQUINE,CHEMBL298470,NA,Medicines for Malaria Venture/GlaxoSmithKline,8-Aminoquinoline antimalarial,Other,No human target,Plasmodium vivax malaria,Plasmodium vivax malaria,EFO_0007445,"P, O, B, F",2018,NA,,Severe
Kybella,Deoxycholic acid,DEOXYCHOLIC ACID,CHEMBL406393,NA,Kythera,Cytolytic drug,Other,No human target,Fat below the chin,body fat distribution,EFO_0004341,S,2015,NA,,Non severe
Kynamro,Mipomersen,MIPOMERSEN,CHEMBL2219536,ENSG00000084674,Genzyme,Oligonucleotide inhibitor of apolipoprotein B100 synthesis,Other,Other indication,Homozygous familial hypercholesterolaemia,homozygous familial hypercholesterolemia,MONDO_0018328,"S, O",2013,TRUE,,Severe
Lampit,Nifurtimox,NIFURTIMOX,CHEMBL290960,NA,Bayer,Nitrofuran antiprotozoal,Other,No human target,Chagas disease,chagas disease,MONDO_0001444,"P, O, A",2020,NA,,Severe
Lartruvo,Olaratumab,OLARATUMAB,CHEMBL1743049,ENSG00000134853,Eli Lilly,PDGFRalpha-blocking antibody,Oncology,Oncology,Soft tissue sarcoma,soft tissue sarcoma,EFO_1001968,"P, O, B, A, F",2016,TRUE,,Severe
Lenvima,Lenvatinib,LENVATINIB,CHEMBL1289601,"ENSG00000037280, ENSG00000128052, ENSG00000102755",Eisai,VEGFR inhibitor,Oncology,Oncology,Thyroid cancer,thyroid cancer,MONDO_0002108,"P, O",2015,TRUE,,Severe
Leqvio,Inclisiran,Inclisiran,CHEMBL3990033,ENSG00000169174,Novartis/Alnylam,PCSK9-targeted siRNA,Other,Other indication,HeFH or ASCVD,coronary atherosclerosis,MONDO_0021661,S,2021,TRUE,,Severe
Libtayo,Cemiplimab,CEMIPLIMAB,CHEMBL4297723,ENSG00000188389,Regeneron/Sanofi,PD1 antibody,Oncology,Oncology,"CSCC, BCC(*), NSCLC(*)",cutaneous squamous cell carcinoma; basal cell carcinoma; non-small cell lung carcinoma,EFO_1001927; EFO_0004193; EFO_0003060,"P, B",2018,TRUE,,Severe
Livmarli,Maralixibat,Maralixibat,CHEMBL363392,ENSG00000125255,Mirum,IBAT inhibitor,Other,Other indication,Pruritus in Alagille syndrome,Alagille syndrome,MONDO_0007318,"P, O, B",2021,TRUE,,Severe
Livtencity,Maribavir,Maribavir,CHEMBL515408,NA,Takeda,CMV pUL97 kinase inhibitor,Other,No human target,Post-transplant CMV infection,NA,NA,"P, O, B",2021,NA,,NA
Lokelma,Sodium zirconium cyclosilicate,SODIUM ZIRCONIUM CYCLOSILICATE,CHEMBL3301592,NA,AstraZeneca,Potassium binder,Other,No human target,Hyperkalaemia,hyperkalemia,HP_0002153,S,2018,NA,,Not concordant
Lonsurf,Tipiracil; trifluridine,TIPIRACIL; TRIFLURIDINE,CHEMBL235668; CHEMBL1129,ENSG00000025708; ENSG00000176890,Taiho,Thymidine phosphorylase inhibitor plus a nucleoside metabolic inhibitor,Oncology,Oncology,Colorectal cancer,colorectal cancer,EFO_0005842,"S, F",2015,TRUE,,Severe
Lorbrena,Lorlatinib,LORLATINIB,CHEMBL3286830,"ENSG00000171094, ENSG00000143924",Pfizer,ALK and ROS1 inhibitor,Oncology,Oncology,ALK-positive NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A",2018,TRUE,,Severe
Lucemyra,Lofexidine,LOFEXIDINE,CHEMBL17860,"ENSG00000150594, ENSG00000274286, ENSG00000184160",US WorldMeds,beta2-adrenoceptor agonist,Other,Other indication,Opioid withdrawal,opioid dependence,EFO_0005611,"P, F",2018,FALSE,Symptomatic,Non severe
Lumakras,Sotorasib,Sotorasib,CHEMBL4535757,ENSG00000133703,Amgen,KRAS-G12C inhibitor,Oncology,Oncology,KRASG12C-mutated NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A, F",2021,TRUE,,Severe
Lumason,Sulfur hexafluoride lipid-type A microspheres,SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES,NA,NA,Bracco,Ultrasound contrast agent,Other,No human target,Cardiovascular imaging,NA,NA,S,2014,NA,,NA
Lumoxiti,Moxetumomab pasudotox,MOXETUMOMAB PASUDOTOX,CHEMBL1743043,"ENSG00000167658, ENSG00000012124",AstraZeneca,CD22-directed antibody‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚àö√´‚Äö√†√∂¬¨¬Ædrug conjugate,Oncology,Oncology,Hairy cell leukaemia,hairy cell leukemia,EFO_1000956,"P, O, F",2018,TRUE,,Severe
Lunsumio,Mosunetuzumab,Mosunetuzumab,CHEMBL4297788,"ENSG00000167286, ENSG00000156738, ENSG00000198851, ENSG00000160654",Roche/Genentech,CD20 _ CD3 bispecific antibody,Oncology,Oncology,Follicular lymphoma,follicular lymphoma,MONDO_0018906,"P, O, B, A",2022,TRUE,,Severe
Lupkynis,Voclosporin,Voclosporin,CHEMBL2218919,ENSG00000138814,Aurinia,Calcineurin inhibitor,Other,Other indication,Lupus nephritis,lupus nephritis,EFO_0005761,"P, F",2021,TRUE,,Severe
Lutathera,Lutetium Lu 177 dotatate,LUTETIUM LU 177 DOTATATE,CHEMBL3989924,"ENSG00000139874, ENSG00000162009, ENSG00000278195, ENSG00000132671, ENSG00000180616",Advanced Accelerator Applications/Novartis,Somatostatin receptor-targeted radiopharmaceutical,Oncology,Oncology,GEP-NETs,digestive system neuroendocrine neoplasm,MONDO_0024503,"P, O, F",2018,TRUE,,Severe
Luzu,Luliconazole,LULICONAZOLE,CHEMBL2105689,NA,Medicis,Azole antifungal,Other,No human target,"Interdigital tinea pedis, tinea cruris and tinea corporis caused by Trichophyton rubrum and Epidermophyton floccosum",tinea,EFO_0007510,S,2013,NA,,Non severe
Lybalvi,Olanzapine; samidorphan,samidorphan; Olanzapine,CHEMBL426084; CHEMBL715,"ENSG00000112038, ENSG00000116329, ENSG00000082556; ENSG00000102468, ENSG00000147246, ENSG00000151577, ENSG00000069696, ENSG00000149295",Alkermes,Atypical antipsychotic and opioid antagonist,Other,Other indication,Schizophrenia and bipolar I disorder,Schizophrenia; bipolar I disorder,MONDO_0005090; EFO_0009963,S,2021,TRUE,,Severe
Lymphoseek kit,Technetium TC 99m tilmanocept,TECHNETIUM TC 99M TILMANOCEPT,CHEMBL2108726,ENSG00000260314,Navidea,Radioactive diagnostic agent,Other,Other indication,Lymphatic mapping in patients with breast cancer or melanoma,breast cancer; melanoma,MONDO_0007254; EFO_0000756,S,2013,FALSE,Imaging,Severe
Lynparza,Olaparib,OLAPARIB,CHEMBL521686,"ENSG00000143799, ENSG00000041880, ENSG00000129484",AstraZeneca,PARP inhibitor,Oncology,Oncology,Advanced BRCA-mutated ovarian cancer,ovarian cancer,MONDO_0008170,"P, O, A, F",2014,TRUE,,Severe
Lytgobi,Futibatinib,Futibatinib,CHEMBL3701238,"ENSG00000068078, ENSG00000077782, ENSG00000160867, ENSG00000066468",Taiho Oncology,FGFR kinase inhibitor,Oncology,Oncology,FGFR2-aberrant intrahepatic cholangiocarcinoma,intrahepatic cholangiocarcinoma,EFO_1001961,"P, O, B, A, F",2022,TRUE,,Severe
Macrilen,Macimorelin,MACIMORELIN,CHEMBL278623,ENSG00000121853,Aeterna Zentaris,Growth hormone secretagogue receptor agonist,Other,Other indication,Diagnosis of adult growth hormone deficiency,short stature due to GHSR deficiency,MONDO_0014403,"S, O",2017,TRUE,,Non severe
Margenza,Margetuximab,MARGETUXIMAB,CHEMBL2364649,ENSG00000141736,MacroGenics,HER2-directed mAb,Oncology,Oncology,HER2-positive breast cancer,HER2 Positive Breast Carcinoma,EFO_1000294,"S, F",2020,TRUE,,Severe
Mavyret,Glecaprevir; pibrentasvir,GLECAPREVIR; PIBRENTASVIR,CHEMBL3545363; CHEMBL3545123,NA; NA,AbbVie,NS3/4A protease inhibitor plus a NS5A inhibitor,Other,No human target,HCV,hepatitis C virus infection,EFO_0003047,"P, B, F",2017,NA,,Severe
Mayzent,Siponimod,SIPONIMOD,CHEMBL2336071,ENSG00000170989,Novartis,S1P receptor modulator,Other,Other indication,Relapsing forms of multiple sclerosis,relapsing-remitting multiple sclerosis,EFO_0003929,S,2019,FALSE,,Severe
Mekinist,Trametinib,TRAMETINIB,CHEMBL2103875,"ENSG00000169032, ENSG00000126934",GSK,MEK1 and MEK2 kinase inhibitor,Oncology,Oncology,Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test,metastatic melanoma,EFO_0002617,"S, O, F",2013,TRUE,,Severe
Mektovi,Binimetinib,BINIMETINIB,CHEMBL3187723,"ENSG00000169032, ENSG00000126934",Array BioPharma,MEK inhibitor,Oncology,Oncology,BRAF-mutated melanoma,melanoma,EFO_0000756,"S, O",2018,TRUE,,Severe
Mepsevii,Vestronidase alfa,VESTRONIDASE ALFA,CHEMBL3707382,ENSG00000169919,Ultragenyx,Recombinant human lysosomal ‚Äö√¢√†‚àö‚â†‚Äö√Ñ√∂‚àö¬¢¬¨√ü-glucuronidase,Other,Other indication,Mucopolysaccharidosis VII,mucopolysaccharidosis type 7,MONDO_0009662,"P, O, F",2017,TRUE,,Severe
Monjuvi,Tafasitamab,TAFASITAMAB,CHEMBL4298047,ENSG00000177455,MorphoSys,CD19-directed mAb,Oncology,Oncology,DLBCL,diffuse large b-cell lymphoma,EFO_0000403,"P, O, B, A, F",2020,TRUE,,Severe
Motegrity,Prucalopride,PRUCALOPRIDE,CHEMBL117287,ENSG00000164270,Shire/Takeda,5-HT4-receptor agonist,Other,Other indication,Chronic idiopathic constipation,constipation disorder,MONDO_0002203,S,2018,FALSE,Symptomatic,Non severe
Mounjaro,Tirzepatide,Tirzepatide,CHEMBL4297839,"ENSG00000010310, ENSG00000112164",Eli Lilly,GIP receptor and GLP1 receptor agonist,Other,Other indication,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,S,2022,TRUE,,Non Severe
Movantik,Naloxegol,NALOXEGOL,CHEMBL2219418,ENSG00000112038,AstraZeneca,Opioid-receptor antagonist,Other,Other indication,Opioid-induced constipation,Constipation,HP_0002019,S,2014,FALSE,Symptomatic,Non severe
Moxidectin,Moxidectin,MOXIDECTIN,CHEMBL2104415,NA,Medicines Development for Global Health,Antihelmintic GABA receptor and glutamate channel modulator,Other,No human target,River blindness,ocular onchocerciasis,EFO_0007398,"P, O",2018,NA,,Not concordant
Mulpleta,Lusutrombopag,LUSUTROMBOPAG,CHEMBL2107831,ENSG00000117400,Shionogi,Thrombopoietin receptor agonist,Other,Other indication,Thrombocytopenia,thrombocytopenia,HP_0001873,"P, F",2018,TRUE,,Not concordant
Myalept,Metreleptin,METRELEPTIN,CHEMBL2107857,ENSG00000116678,Amylin,Leptin analogue,Other,Other indication,Leptin deficiency in patients with congenital or acquired generalized lipodystrophy,congenital generalized lipodystrophy,EFO_1000681,"P, O, F",2014,TRUE,,Severe
Natpara,Parathyroid hormone,PARATHYROID HORMONE,CHEMBL2108078,ENSG00000160801,NPS Pharma,Hormonal injection,Other,Other indication,Hypocalcaemia in patients with hypoparathyroidism,hypoparathyroidism; Hypocalcemia,EFO_0009451; HP_0002901,"S, O",2015,TRUE,,Not concordant
Nerlynx,Neratinib,NERATINIB,CHEMBL180022,"ENSG00000178568, ENSG00000146648, ENSG00000141736",Puma Biotechnology,"EGFR, HER2 and HER4 irreversible kinase inhibitor",Oncology,Oncology,HER2-overexpressed breast cancer,HER2 Positive Breast Carcinoma,EFO_1000294,S,2017,TRUE,,Severe
Nesina,Alogliptin,ALOGLIPTIN,CHEMBL376359,ENSG00000197635,Takeda,DPP4 inhibitor,Other,Other indication,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,S,2013,TRUE,,Non Severe
Netspot,Gallium Ga-68 dotatate,GALLIUM GA-68 DOTATATE,CHEMBL4297340,ENSG00000180616,Advanced Accelerator Applications,Radioactive diagnostic,Other,Other indication,Neuroendocrine tumours,neuroendocrine neoplasm,EFO_1001901,"P, O",2016,TRUE,,Severe
Neuraceq,Florbetaben-F18,FLORBETABEN-F18,CHEMBL566752,ENSG00000142192,Piramal Imaging,Radioactive diagnostic agent,Other,Other indication,Imaging of the brain to estimate density of neuritic amyloid-beta plaques,neuritic plaque measurement; Alzheimer disease,EFO_0006798; MONDO_0004975,S,2014,TRUE,Imaging,Severe
Nexletol,Bempedoic acid,BEMPEDOIC ACID,CHEMBL3545313,ENSG00000131473,Esperion Therapeutics,ACL inhibitor,Other,Other indication,HeFH or atherosclerotic cardiovascular disease,atherosclerosis; familial hypercholesterolemia,EFO_0003914; EFO_0004911,S,2020,FALSE,,Severe
NexoBrid,Anacaulase,Anacaulase,NA,NA,Mediwound,Proteolytic enzymes from pineapple plants,Other,No human target,Eschar removal after thermal burns,NA,NA,"S, O",2022,NA,,NA
Nextstellis,Drospirenone; estetrol,Drospirenone; estetrol,CHEMBL1509; CHEMBL1230314,"ENSG00000151623, ENSG00000082175; ENSG00000091831, ENSG00000140009",Mayne Pharma,Spironolactone and oestrogen analogues,Other,Other indication,To prevent pregnancy,reproductive behaviour measurement,EFO_0007862,S,2021,TRUE,,Non severe
Nexviazyme,Avalglucosidase alfa,Avalglucosidase alfa,CHEMBL4594320,ENSG00000171298,Sanofi,Recombinant alpha-glucosidase,Other,Other indication,Pompe disease,glycogen storage disease II,MONDO_0009290,"P, O, B, F",2021,TRUE,,Severe
Ninlaro,Ixazomib,IXAZOMIB,CHEMBL2141296,"ENSG00000165916, ENSG00000240065, ENSG00000159377, ENSG00000108671, ENSG00000100804, ENSG00000161057, ENSG00000154611, ENSG00000159352, ENSG00000100902, ENSG00000013275, ENSG00000173692, ENSG00000101182, ENSG00000103035, ENSG00000129084, ENSG00000142507, ENSG00000222028, ENSG00000197170, ENSG00000175166, ENSG00000205220, ENSG00000100764, ENSG00000277791, ENSG00000136930, ENSG00000099341, ENSG00000163636, ENSG00000185627, ENSG00000127922, ENSG00000115233, ENSG00000087191, ENSG00000108344, ENSG00000204264, ENSG00000100519, ENSG00000100567, ENSG00000143106, ENSG00000126067, ENSG00000130706, ENSG00000106588, ENSG00000008018, ENSG00000041357",Takeda,Oral proteasome inhibitor,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O",2015,TRUE,,Severe
Northera,Droxidopa,DROXIDOPA,CHEMBL2103827,"ENSG00000169252, ENSG00000170214, ENSG00000043591, ENSG00000120907, ENSG00000274286, ENSG00000184160, ENSG00000188778, ENSG00000150594, ENSG00000171873",Lundbeck,Synthetic amino-acid precursor of noradrenaline; MOA unknown,Other,Other indication,Light-headedness in patients with neurogenic orthostatic hypotension,primary orthostatic hypotension,MONDO_0015914,"P, O, A, F",2014,TRUE,,Non severe
Nourianz,Istradefylline,ISTRADEFYLLINE,CHEMBL431770,ENSG00000128271,Kyowa Kirin,Adenosine receptor antagonist,Other,Other indication,Parkinson disease episodes,Parkinson disease,MONDO_0005180,S,2019,TRUE,,Severe
Nubeqa,Darolutamide,DAROLUTAMIDE,CHEMBL4297185,ENSG00000169083,Bayer,Androgen receptor inhibitor,Oncology,Oncology,Prostate cancer,prostate cancer,MONDO_0008315,"P, F",2019,TRUE,,Severe
Nucala,Mepolizumab,MEPOLIZUMAB,CHEMBL2108429,ENSG00000113525,GlaxoSmithKline,IL-5 antagonist,Other,Other indication,Severe asthma,Status Asthmaticus,EFO_0008590,"S, F",2015,TRUE,,Severe
Nulibry,Fosdenopterin,Fosdenopterin,CHEMBL2338675,ENSG00000164172,BridgeBio,cPMP,Other,Other indication,MoCD type A,sulfite oxidase deficiency due to molybdenum cofactor deficiency,MONDO_0020480,"P, O, B",2021,TRUE,,Severe
Nuplazid,Pimavanserin,PIMAVANSERIN,CHEMBL2111101,ENSG00000102468,Acadia Pharmaceuticals,Atypical antipsychotic,Other,Other indication,Hallucinations and delusions associated with Parkinson disease psychosis,Parkinson disease; psychosis,MONDO_0005180; EFO_0005407,"P, B",2016,TRUE,,Severe
Nurtec ODT,Rimegepant,RIMEGEPANT,CHEMBL2178422,ENSG00000064989,Biohaven,CGRP receptor antagonist,Other,Other indication,Migraine,migraine disorder,MONDO_0005277,S,2020,TRUE,,Non Severe
Nuzyra,Omadacycline,OMADACYCLINE,CHEMBL1689772,NA,Paratek Pharmaceuticals,Tetracycline antibiotic,Other,No human target,CABP and ABSSSI,bacterial pneumonia; skin disease caused by bacterial infection,EFO_1001272; MONDO_0024295,"P, F",2018,NA,,Severe
Ocaliva,Obeticholic acid,OBETICHOLIC ACID,CHEMBL566315,ENSG00000012504,Intercept,FXR agonist,Other,Other indication,Primary biliary cholangitis,primary biliary cirrhosis,EFO_1001486,"P, O, A, F",2016,TRUE,,Severe
Ocrevus,Ocrelizumab,OCRELIZUMAB,CHEMBL2108041,ENSG00000156738,Roche/Genentech,CD20-directed cytolytic antibody,Other,Other indication,Relapsing or primary progressive forms of multiple sclerosis,chronic progressive multiple sclerosis,EFO_0003840,"P, B, F",2017,FALSE,,Severe
Odomzo,Sonidegib,SONIDEGIB,CHEMBL2105737,ENSG00000128602,Novartis,Smoothened inhibitor,Oncology,Oncology,Basal cell carcinoma,basal cell carcinoma,EFO_0004193,S,2015,TRUE,,Non Severe
Ofev,Nintedanib,NINTEDANIB,CHEMBL502835,"ENSG00000102755, ENSG00000037280, ENSG00000128052, ENSG00000066468, ENSG00000077782, ENSG00000160867, ENSG00000134853, ENSG00000113721, ENSG00000068078",Boehringer Ingelheim,"Kinase inhibitor against PDGFRs, FGFRs, VEGFRs and FLT3",Other,Other indication,IPF (idiopathic pulmonary fibrosis),idiopathic pulmonary fibrosis,EFO_0000768,"P, O, B, F",2014,TRUE,,Severe
Olinvyk,Oliceridine,OLICERIDINE,CHEMBL2443262,ENSG00000112038,Trevena,Opioid receptor agonist,Other,Other indication,Acute pain,pain,EFO_0003843,"S, F",2020,FALSE,Symptomatic,Non Severe
Olumiant,Baricitinib,BARICITINIB,CHEMBL2105759,"ENSG00000096968, ENSG00000162434",Incyte/Eli Lilly,JAK inhibitor,Other,Other indication,Rheumatoid arthritis,rheumatoid arthritis,EFO_0000685,S,2018,TRUE,,Severe
Olysio,Simeprevir,SIMEPREVIR,CHEMBL501849,NA,Janssen,HCV NS3/4A protease inhibitor,Other,No human target,"Chronic HCV infection, as a component of a combination antiviral treatment regimen",hepatitis C virus infection,EFO_0003047,"P, F",2013,NA,,Severe
Omegaven,Fish oil triglycerides,FISH OIL TRIGLYCERIDES,CHEMBL4297535,NA,Fresenius,Mixture of fatty acids,Other,No human target,Parenteral nutrition-associated cholestasis,cholestasis,MONDO_0001751,"P, O, F",2018,NA,,Severe
Omlonti,Omidenepag isopropyl,Omidenepag isopropyl,CHEMBL4297666,ENSG00000125384,Santen,Prostaglandin E2 receptor agonist,Other,Other indication,Intraocular pressure in open-angle glaucoma or ocular hypertension,"ocular hypertension, open-angle glaucoma",EFO_1001069; EFO_0004190,S,2022,FALSE,Symptomatic,Severe
Ongentys,Opicapone,OPICAPONE,CHEMBL1089318,ENSG00000093010,Neurocrine,COMT inhibitor,Other,Other indication,Parkinson disease,parkinson disease,MONDO_0005180,S,2020,TRUE,,Severe
Onpattro,Patisiran,PATISIRAN,CHEMBL3989987,ENSG00000118271,Alnylam Pharmaceuticals,TTR-directed small interfering RNA,Other,Other indication,Hereditary TTR-mediated amyloidosis,hereditary ATTR amyloidosis,MONDO_0017132,"P, O, B, F",2018,TRUE,,Severe
Opdivo,Nivolumab,NIVOLUMAB,CHEMBL2108738,ENSG00000188389,Bristol-Myers Squibb,PD1 inhibitor,Oncology,Oncology,Unresectable or metastatic melanoma,metastatic melanoma,EFO_0002617,"P, O, B, A, F",2014,FALSE,,Severe
Opdualag,Relatlimab; nivolumab,Relatlimab; nivolumab,CHEMBL3990044; CHEMBL2108738,ENSG00000089692; ENSG00000188389,Bristol Myers Squibb,LAG3-targeted mAb plus PD1-targeted mAb,Oncology,Oncology,Melanoma,melanoma,EFO_0000756,"P, O, F",2022,TRUE,,Severe
Opsumit,Macitentan,MACITENTAN,CHEMBL2103873,"ENSG00000136160, ENSG00000151617",Actelion,Endothelin receptor antagonist,Other,Other indication,Pulmonary arterial hypertension,pulmonary arterial hypertension,EFO_0001361,"S, O",2013,TRUE,,Severe
Orbactiv,Oritavancin,ORITAVANCIN,CHEMBL1688530,NA,The Medicines Company,Semi-synthetic lipoglycopeptide,Other,No human target,ABSSSI (Acute Bacterial Skin and Skin Structure Infections),staphylococcal skin infections,EFO_1001849,P,2014,NA,,Non Severe
Orgovyx,Relugolix,RELUGOLIX,CHEMBL1800159,ENSG00000109163,Myovant Sciences,GnRH receptor antagonist,Oncology,Oncology,Prostate cancer,prostate cancer,MONDO_0008315,P,2020,TRUE,,Severe
Orilissa,Elagolix sodium,ELAGOLIX SODIUM,CHEMBL502182,ENSG00000109163,AbbVie,GnRH receptor antagonist,Other,Other indication,Pain associated with endometriosis,adenomyosis; pain,MONDO_0010888; EFO_0003843,P,2018,TRUE,,Non Severe
Orkambi,Ivacaftor; lumacaftor,IVACAFTOR; LUMACAFTOR,CHEMBL2010601; CHEMBL2103870,ENSG00000001626; ENSG00000001626,Vertex,CFTR potentiator plus CFTR corrector,Other,Other indication,Cystic fibrosis in patients with homozygous DF508 CFTR mutation,cystic fibrosis,MONDO_0009061,"P, O, B, F",2015,TRUE,,Severe
Orladeyo,Berotralstatc,BEROTRALSTAT,CHEMBL4594271,ENSG00000164344,BioCryst,Plasma kallikrein inhibitor,Other,#N/A,Hereditary angioedema,hereditary angioedema,MONDO_0019623,"S, O, F",2020,FALSE,,Severe
Osphena,Ospemifene,OSPEMIFENE,CHEMBL2105395,"ENSG00000140009, ENSG00000091831",Shionogi,Oestrogen receptor modulator,Other,Other indication,Moderate to severe dyspareunia due to menopause,Dyspareunia; menopause,HP_0030016; EFO_0003922,S,2013,TRUE,,Non Severe
Otezla,Apremilast,APREMILAST,CHEMBL514800,"ENSG00000184588, ENSG00000065989, ENSG00000105650, ENSG00000113448",Celgene,Phosphodiesterase 4 inhibitor,Other,Other indication,Psoriatic arthritis and plaque psoriasis,psoriatic arthritis; psoriasis vulgaris,EFO_0003778; EFO_1001494,S,2014,TRUE,,Severe
Oxbryta,Voxelotor,VOXELOTOR,CHEMBL4101807,"ENSG00000206172, ENSG00000244734, ENSG00000188536",Global Blood Therapeutics,Haemoglobin S polymerization inhibitor,Other,Other indication,SCD (sickle cell disease),sickle cell anemia,MONDO_0011382,"P, O, B, A, F",2019,TRUE,,Severe
Oxervate,Cenegermin,CENEGERMIN,CHEMBL4297852,"ENSG00000140538, ENSG00000148053, ENSG00000198400",Domp‚Äö√Ñ√∂‚àö‚Ä†‚àö‚àÇ¬¨¬®¬¨¬©,Recombinant NGF,Other,Other indication,Neurotrophic keratitis,keratitis,EFO_0009449,"P, O, B, F",2018,TRUE,,Non Severe
Oxlumo,Lumasiran,LUMASIRAN,CHEMBL4297779,ENSG00000101323,Alnylam,HAO1-directed siRNA,Other,Other indication,Hyperoxaluria type 1,primary hyperoxaluria type 1,MONDO_0009823,"P, O, B",2020,FALSE,,Severe
Ozempic,Semaglutide,SEMAGLUTIDE,CHEMBL2108724,ENSG00000112164,Novo Nordisk,GLP1 receptor agonist,Other,Other indication,Type 2 diabetes mellitus,type 2 diabetes mellitus,MONDO_0005148,S,2017,TRUE,,Non Severe
PSMA-11 Ga-68,PSMA-11 Ga-68,PSMA-11 GA-68,CHEMBL4297335,ENSG00000142515,UCLA,Radioactive diagnostic,Other,Other indication,"Imaging, prostate cancer",prostate carcinoma,EFO_0001663,S,2020,TRUE,Imaging,Severe
Padcev,Enfortumab vedotin,ENFORTUMAB VEDOTIN,CHEMBL3301589,"ENSG00000143217, ENSG00000101162, ENSG00000167552, ENSG00000261456, ENSG00000127824, ENSG00000123416, ENSG00000258947, ENSG00000198033, ENSG00000188229, ENSG00000152086, ENSG00000137267, ENSG00000104833, ENSG00000167553, ENSG00000137285, ENSG00000196230, ENSG00000176014",Astellas,Nectin-4-directed ADC,Oncology,Oncology,Urothelial cancers,urothelial neoplasm,MONDO_0024337,"P, B, A",2019,TRUE,,Severe
Palynziq,Pegvaliase,PEGVALIASE,CHEMBL4297802,NA,BioMarin Pharmaceutical,PAL replacement therapy,Other,No human target,Phenylketonuria,phenylketonuria,MONDO_0009861,"P, O, F",2018,NA,,Severe
Parsabiv,Etelcalcetide,VELCALCETIDE,CHEMBL3545184,ENSG00000036828,Amgen/Kai Pharmaceuticals,Calcium-sensing receptor agonist,Other,Other indication,Secondary hyperparathyroidism in patients with chronic kidney disease on haemodialysis,hyperparathyroidism,EFO_0008506,S,2017,TRUE,,Non Severe
Pemazyre,Pemigatinib,PEMIGATINIB,CHEMBL4297522,"ENSG00000066468, ENSG00000068078, ENSG00000077782",Incyte,FGFR1-3 kinase inhibitor,Oncology,Oncology,Cholangiocarcinoma,cholangiocarcinoma,EFO_0005221,"P, O, B, A",2020,TRUE,,Severe
Pepaxto,Melphalan flufenamide,Melphalan flufenamide,CHEMBL4303060,NA,Oncopeptides,Peptide-conjugated alkylating drug,Oncology,,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O, A",2021,NA,,Severe
Pifeltro,Doravirine,DORAVIRINE,CHEMBL2364608,NA,Merck & Co.,NNRTI,Other,No human target,HIV,hiv infection,EFO_0000764,S,2018,NA,,Severe
Piqray,Alpelisib,ALPELISIB,CHEMBL2396661,ENSG00000121879,Novartis,PI3K inhibitor,Oncology,Oncology,Breast cancer,breast cancer,MONDO_0007254,P,2019,TRUE,,Severe
Pizensy,Lactitol,LACTITOL,CHEMBL1661,NA,Braintree Labs,Osmotic laxative,Other,No human target,Chronic idiopathic constipation,Chronic constipation,HP_0012450,S,2020,NA,,Non severe
Plegridy,Peginterferon beta-1A,PEGINTERFERON BETA-1A,CHEMBL2108677,"ENSG00000159110, ENSG00000142166",Biogen Idec,Long-acting interferon-beta1A,Other,Other indication,Relapsing multiple sclerosis,relapsing-remitting multiple sclerosis,EFO_0003929,S,2014,FALSE,,Severe
Pluvicto,Lutetium Lu-177 vipivotide tetraxetan,Lutetium Lu-177 vipivotide tetraxetan,CHEMBL4594406,ENSG00000142515,Novartis,PSMA-binding radioligand therapeutic agent,Oncology,Oncology,PSMA-positive prostate cancer,prostate carcinoma,EFO_0001663,"P, B",2022,TRUE,,Severe
Polivy,Polatuzumab vedotin,POLATUZUMAB VEDOTIN,CHEMBL3301582,"ENSG00000198033, ENSG00000167552, ENSG00000261456, ENSG00000176014, ENSG00000258947, ENSG00000123416, ENSG00000101162, ENSG00000188229, ENSG00000152086, ENSG00000007312, ENSG00000137285, ENSG00000167553, ENSG00000196230, ENSG00000137267, ENSG00000127824, ENSG00000104833",Roche,CD79b-directed ADC,Oncology,Oncology,Diffuse large B-cell lymphoma,diffuse large b-cell lymphoma,EFO_0000403,"P, O, B, A",2019,TRUE,,Severe
Pomalyst,Pomalidomide,POMALIDOMIDE,CHEMBL43452,"ENSG00000167986, ENSG00000139842, ENSG00000113851, ENSG00000100387",Celgene,Immunomodulatory antineoplastic agent,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"S, O, F",2013,TRUE,,Severe
Ponvory,Ponesimod,Ponesimod,CHEMBL1096146,ENSG00000170989,J&J,S1P receptor modulator,Other,Other indication,Relapsing multiple sclerosis,multiple sclerosis,MONDO_0005301,S,2021,TRUE,,Severe
Portrazza,Necitumumab,NECITUMUMAB,CHEMBL1743047,ENSG00000146648,Eli Lilly,EGFR antagonist,Oncology,Oncology,NSCLC,non-small cell lung carcinoma,EFO_0003060,"S, O, F",2015,TRUE,,Severe
Poteligeo,Mogamulizumab,MOGAMULIZUMAB,CHEMBL1743041,ENSG00000183813,Kyowa Hakko Kirin,CCR4 antibody,Oncology,Oncology,mycosis fungoides or Sezary syndrome,mycosis fungoides,EFO_1001051,"P, O, B",2018,TRUE,,Severe
Praluent,Alirocumab,ALIROCUMAB,CHEMBL2109540,ENSG00000169174,Sanofi,PCSK9 inhibitor,Other,Other indication,LDL lowering,LDL cholesterol change measurement,EFO_0007804,P,2015,TRUE,,Non Severe
Praxbind,Idarucizumab,IDARUCIZUMAB,CHEMBL3544996,NA,Boehringer Ingelheim,Dabigatran-binding mAb fragment,Other,No human target,Reversal of anticoagulant effects of dabigatran,response to anticoagulant,GO_0061476,"P, O, B, A",2015,NA,,Non Severe
Pretomanid,Pretomanid,PRETOMANID,CHEMBL227875,NA,Pfizer/Mylan,Antimycobacterial,Other,No human target,Tuberculosis,tuberculosis,MONDO_0018076,"P, O, F",2019,NA,,Severe
Prevymis,Letermovir,LETERMOVIR,CHEMBL1241951,NA,Merck & Co.,CMV DNA terminase complex inhibitor,Other,No human target,Prophylaxis of CMV (cytomegalovirus),cytomegalovirus infection,EFO_0001062,"P, O, B, F",2017,NA,,Severe
Pylarify,Piflufolastat F-18,Piflufolastat F-18,CHEMBL4297334,ENSG00000086205,Progenics,Radiolabelled PSMA imaging agent,Other,Other indication,Prostate cancer imaging,prostate carcinoma,EFO_0001663,P,2021,FALSE,Imaging,Severe
Pyrukynd,Mitapivat,Mitapivat,CHEMBL4299940,ENSG00000143627,Agios,Pyruvate kinase activator,Other,Other indication,Haemolytic anaemia due to PK deficiency,hemolytic anemia,EFO_0005558,"P, O, F",2022,TRUE,,Severe
Qelbree,Viloxazine,Viloxazine,CHEMBL306700,ENSG00000103546,Supernus,SNRI,Other,Other indication,ADHD,attention deficit hyperactivity disorder,EFO_0003888,S,2021,FALSE,,Non Severe
Qinlock,Ripretinib,RIPRETINIB,CHEMBL4216467,"ENSG00000157404, ENSG00000134853",Deciphera,KIT and PDGFRA kinase inhibitor,Oncology,Oncology,GIST,gastrointestinal stromal tumor,MONDO_0011719,"P, O, B, F",2020,TRUE,,Severe
Qulipta,Atogepant,Atogepant,CHEMBL3991065,ENSG00000064989,AbbVie,CGRP receptor antagonist,Other,Other indication,Episodic migraine,migraine disorder,MONDO_0005277,S,2021,TRUE,,Non Severe
Quviviq,Daridorexant,Daridorexant,CHEMBL4297590,"ENSG00000137252, ENSG00000121764",Idorsia,Orexin receptor antagonist,Other,Other indication,Insomnia,insomnia,EFO_0004698,S,2022,TRUE,,Non Severe
Radicava,Edaravone,EDARAVONE,CHEMBL290916,NA,Mitsubishi Tanabe,Unknown (radical scavenger),Other,No human target,ALS (amyotrophic lateral sclerosis),amyotrophic lateral sclerosis,MONDO_0004976,"S, O",2017,NA,,Severe
Rapivab,Peramivir,PERAMIVIR; PERAMIVIR,CHEMBL3989402; CHEMBL139367,NA; NA,BioCryst,Neuraminidase inhibitor,Other,No human target,Influenza infection,influenza,EFO_0007328,"S, F",2014,NA,,Non Severe
Reblozyl,Luspatercept,LUSPATERCEPT,CHEMBL3039545,"ENSG00000105329, ENSG00000092969, ENSG00000119699",Celgene/BMS,Erythroid maturation agent,Other,Other indication,Anaemia in beta-thalassaemia,beta thalassemia; anemia,MONDO_0019402; MONDO_0002280,"P, O, F",2019,TRUE,,Severe
Recarbrio,Cilastatin; imipenem; relebactam,CILASTATIN; IMIPENEM; RELEBACTAM,CHEMBL766; CHEMBL148; CHEMBL3301605,ENSG00000015413; NA; NA,Merck & Co.,"A renal dehydropeptidase inhibitor, a penem antibacterial and a beta-lactamase inhibitor",Other,No human target,Complicated urinary tract and complicated intra-abdominal infections,urinary tract infection,EFO_0003103,"P, F",2019,NA,,Non Severe
Relyvrio,Sodium phenylbutyrate; taurursodiol,Sodium phenylbutyrate; taurursodiol,CHEMBL1746; CHEMBL272427,NA; NA,Amylyx,Mechanism unknown,Other,No human target,Amyotrophic lateral sclerosis,amyotrophic lateral sclerosis,MONDO_0004976,"P, O",2022,NA,,Severe
Repatha,Evolocumab,EVOLOCUMAB,CHEMBL2364655,ENSG00000169174,Amgen,PCSK9 inhibitor,Other,Other indication,LDL lowering,LDL cholesterol change measurement,EFO_0007804,"S, O",2015,TRUE,,Non Severe
Retevmo,Selpercatinib,SELPERCATINIB,CHEMBL4559134,"ENSG00000108091, ENSG00000165731, ENSG00000170759",Eli Lilly/Loxo Oncology,RET kinase inhibitor,Oncology,Oncology,RET fusion-positive NSCLC and thyroid cancer,non-small cell lung carcinoma; thyroid cancer,EFO_0003060; MONDO_0002108,"P, O, B, A",2020,TRUE,,Severe
Revcovi,Elapegademase,ELAPEGADEMASE,CHEMBL3990026,ENSG00000196839,Leadiant Biosciences,Recombinant adenosine deaminase,Other,Other indication,ADA-SCID,"severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency",MONDO_0007064,"P, O, F",2018,TRUE,,Severe
Rexulti,Brexpiprazole,BREXPIPRAZOLE,CHEMBL2105760,"ENSG00000149295, ENSG00000178394, ENSG00000102468",Otsuka,Atypical antipsychotic,Other,Other indication,MDD and schizophrenia,major depressive disorder; schizophrenia,MONDO_0002009; MONDO_0005090,S,2015,TRUE,,Severe
Reyvow,Lasmiditan,LASMIDITAN,CHEMBL3039520,ENSG00000179097,Eli Lilly,Serotonin (5-HT) 1F receptor agonist,Other,Other indication,Migraine with or without aura,migraine disorder,MONDO_0005277,S,2019,FALSE,Symptomatic,Non Severe
Rezlidhia,Olutasidenib,Olutasidenib,CHEMBL4297610,ENSG00000138413,Rigel/Forma,IDH1 inhibitor,Oncology,Oncology,IDH1-mutated AML,acute myeloid leukemia,EFO_0000222,"S, O",2022,TRUE,,Severe
Rezurock,Belumosudil,Belumosudil,CHEMBL2005186,"ENSG00000134318, ENSG00000067900",Kadmon,ROCK2 kinase inhibitor,Other,Other indication,Chronic GVHD,graft versus host disease,MONDO_0013730,"P, O, B",2021,FALSE,,Severe
Rhopressa,Netarsudil,NETARSUDIL,CHEMBL4594250,"ENSG00000134318, ENSG00000067900",Aerie Pharmaceuticals,RHO kinase inhibitor,Other,Other indication,Open-angle glaucoma or ocular hypertension,open-angle glaucoma; ocular hypertension,EFO_0004190; EFO_1001069,P,2017,FALSE,,Severe
Rinvoq,Upadacitinib,UPADACITINIB,CHEMBL3622821,"ENSG00000162434, ENSG00000096968, ENSG00000105397, ENSG00000105639",AbbVie,JAK inhibitor,Other,Other indication,Rheumatoid arthritis,rheumatoid arthritis,EFO_0000685,S,2019,TRUE,,Severe
Rolvedon,Eflapegrastim,Eflapegrastim,CHEMBL3833384,ENSG00000119535,Spectrum,Leukocyte growth factor,Other,Other indication,"Incidence of infection in non-myeloid malignancies, with myelosuppressive drugs",infection,EFO_0000544,S,2022,TRUE,,Severe
Rozlytrek,Entrectinib,ENTRECTINIB,CHEMBL1983268,"ENSG00000148053, ENSG00000198400, ENSG00000140538, ENSG00000047936, ENSG00000171094",Roche,"TRKA, TRKB, TRKC, ROS1 and ALK inhibitor",Oncology,Oncology,NTRK fusion-positive solid tumours and ROS1-positive NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A",2019,TRUE,,Severe
Rubraca,Rucaparib,RUCAPARIB,CHEMBL1173055,"ENSG00000041880, ENSG00000129484, ENSG00000143799",Clovis Oncology,PARP inhibitor,Oncology,Oncology,BRCA-positive ovarian cancer,ovarian cancer,MONDO_0008170,"P, O, B, A",2016,TRUE,,Severe
Rukobia,Fostemsavir,FOSTEMSAVIR,CHEMBL3301594,NA,ViiV Healthcare,Attachment inhibitor,Other,No human target,HIV,hiv infection,EFO_0000764,"P, B, F",2020,NA,,Severe
Rybrevant,Amivantamab,Amivantamab,CHEMBL4297774,"ENSG00000105976, ENSG00000146648",J&J,EGFRxMETR bispecific antibody,Oncology,Oncology,EGFR exon 20-mutated NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, B, A",2021,TRUE,,Severe
Rydapt,Midostaurin,MIDOSTAURIN,CHEMBL608533,"ENSG00000163932, ENSG00000115825, ENSG00000166501, ENSG00000171132, ENSG00000163558, ENSG00000184304, ENSG00000065675, ENSG00000126583, ENSG00000027075, ENSG00000067606, ENSG00000154229, ENSG00000128052, ENSG00000122025, ENSG00000157404, ENSG00000134853, ENSG00000113721",Novartis,FLT3 inhibitor,Oncology,Oncology,FLT3-positive AML,"acute myeloid leukemia, FLT3 internal tandem duplication",MONDO_0100415,"P, O, B, F",2017,TRUE,,Severe
Rylaze,Asparaginase erwinia chrysanthemi,Asparaginase erwinia chrysanthemi,CHEMBL1863514,NA,Jazz,Recombinant asparagine-specific enzyme,Oncology,,"ALL and LBL, in patients allergic to E. coli-derived products",acute lymphoblastic leukemia; lymphoblastic lymphoma,EFO_0000220; MONDO_0000873,"S, O, F",2021,NA,,Severe
Saphnelo,Anifrolumab,Anifrolumab,CHEMBL2364653,ENSG00000142166,AstraZeneca,IFNAR-targeted mAb,Other,Other indication,SLE,systemic lupus erythematosus,MONDO_0007915,"S, F",2021,TRUE,,Severe
Sarclisa,Isatuximab,ISATUXIMAB,CHEMBL3545131,ENSG00000004468,Sanofi,CD38-directed mAb,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"S, O",2020,TRUE,,Severe
Savaysa,Edoxaban,EDOXABAN,CHEMBL1269025,ENSG00000126218,Daiichi Sankyo,Factor Xa inhibitor,Other,Other indication,"Risk of stroke and systemic embolism in NVAF, and deep vein thrombosis",atrial fibrillation; deep vein thrombosis,EFO_0000275; EFO_0003907,S,2015,TRUE,,Severe
Scemblix,Asciminib,Asciminib,CHEMBL4208229,ENSG00000097007,Novartis,ABL/BCR-ABL1  kinase inhibitor,Oncology,Oncology,Ph+ CML,Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive,EFO_1000131,"P, O, B, A, F",2021,TRUE,,Severe
Scenesse,Afamelanotide,AFAMELANOTIDE,CHEMBL441738,ENSG00000258839,Clinuvel,Melanocortin 1 receptor agonist,Other,Other indication,Erythropoietic protoporphyria,erythropoietic protoporphyria,MONDO_0001676,"P, O, F",2019,TRUE,,Severe
Seysara,Sarecycline,SARECYCLINE,CHEMBL2364632,NA,Allergan,Tetracycline antibiotic,Other,No human target,Severe acne vulgaris,acne,EFO_0003894,S,2018,NA,,Non Severe
Siliq,Brodalumab,BRODALUMAB,CHEMBL1742996,ENSG00000177663,Valeant Pharmaceuticals,IL-17RA antagonist,Other,Other indication,Plaque psoriasis,psoriasis vulgaris,EFO_1001494,S,2017,TRUE,,Non severe
Sivextro,Tedizolid,TEDIZOLID,CHEMBL1257051,NA,Cubist,Oxazolidinone-class antibacterial,Other,No human target,ABSSSI (Acute Bacterial Skin and Skin Structure Infections),staphylococcal skin infections,EFO_1001849,P,2014,NA,,Non Severe
Skyrizi,Risankizumab,RISANKIZUMAB,CHEMBL3990029,"ENSG00000110944, ENSG00000113302",AbbVie,IL-23 antagonist,Other,Other indication,Plaque psoriasis,psoriasis vulgaris,EFO_1001494,S,2019,TRUE,,Non severe
Skytrofa,Lonapegsomatropin,Lonapegsomatropin,CHEMBL4298185,ENSG00000112964,Ascendis Pharma,PEGylated human growth hormone,Other,Other indication,Growth failure due to GHD,Growth delay,HP_0001510,"S, O",2021,TRUE,,Non Severe
Sogroya,Somapacitan,SOMAPACITAN,CHEMBL3707290,ENSG00000112964,Novo Nordisk,Growth hormone analogue,Other,Other indication,Growth hormone deficiency,short stature due to partial GHR deficiency,MONDO_0011420,S,2020,TRUE,,Non Severe
Solosec,Secnidazole,SECNIDAZOLE,CHEMBL498847,NA,Lupin,Nitroimidazole antimicrobial,Other,No human target,Bacterial vaginosis,bacterial vaginosis,EFO_0003932,"P, F",2017,NA,,Non Severe
Sotyktu,Deucravacitinib,Deucravacitinib,CHEMBL4435170,ENSG00000105397,Bristol Myers Squibb,TYK2 inhibitor,Other,Other indication,Plaque psoriasis,psoriasis vulgaris,EFO_1001494,S,2022,TRUE,,Non severe
Sovaldi,Sofosbuvir,SOFOSBUVIR,CHEMBL1259059,NA,Gilead,HCV nucleotide analogue NS5B polymerase inhibitor,Other,No human target,"Chronic HCV infection, as a component of a combination antiviral treatment regimen",hepatitis C virus infection,EFO_0003047,"P, B, F",2013,NA,,Severe
Spevigo,Spesolimab,Spesolimab,CHEMBL4297911,"ENSG00000115598, ENSG00000196083",Boehringer Ingelheim,IL-36R-targeted mAb,Other,Other indication,Generalized pustular psoriasis flares,"psoriasis 14, pustular",MONDO_0013626,"P, O, B",2022,FALSE,,Not concordant
Spinraza,Nusinersen,NUSINERSEN,CHEMBL3301572,ENSG00000205571,Biogen/Ionis Pharmaceuticals,ASO designed to target SMN2 pre-mRNA,Other,Other indication,Spinal muscular atrophy,spinal muscular atrophy,EFO_0008525,"P, O, F",2016,TRUE,,Severe
Steglatro,Ertugliflozin,ERTUGLIFLOZIN,CHEMBL1770248,ENSG00000140675,Merck & Co./Pfizer,SGLT2 inhibitor,Other,Other indication,Type 2 diabetes mellitus,type 2 diabetes mellitus,MONDO_0005148,S,2017,TRUE,,Non Severe
Strensiq,Asfotase alfa,ASFOTASE ALFA,CHEMBL2108311,ENSG00000162551,Alexion,Alkaline phosphatase,Other,Other indication,Hypophosphatasia,hypophosphatasia,MONDO_0018570,"P, O, B, F",2015,TRUE,,Severe
Striverdi Respimat,Olodaterol,OLODATEROL,CHEMBL605846,ENSG00000169252,Boehringer Ingelheim,Long-acting beta2-adrenoceptor agonist,Other,Other indication,COPD,chronic obstructive pulmonary disease,EFO_0000341,S,2014,TRUE,,Severe
Sunlenca,Lenacapavir,Lenacapavir,CHEMBL4594438,NA,Gilead,HIV-1 capsid inhibitor,Other,No human target,HIV-1 infection,HIV-1 infection,EFO_0000180,"P, B, F",2022,NA,,NA
Sunosi,Solriamfetol,SOLRIAMFETOL,CHEMBL4297620,NA,Jazz,Dopamine and noradrenaline reuptake inhibitor,Other,No human target,Excessive sleepiness due to narcolepsy or obstructive sleep apnoea,hypersomnia; narcolepsy; obstructive sleep apnea,EFO_0005246; MONDO_0021107; EFO_0003918,"S, O",2019,NA,,Severe
Sylvant,Siltuximab,SILTUXIMAB,CHEMBL1743070,ENSG00000136244,Janssen Biotech,IL-6-specific antibody,Other,Other indication,Multicentric Castleman's disease,Castleman disease,MONDO_0015564,"P, O",2014,TRUE,,Severe
Symdeko,Tezacaftor; ivacaftor,TEZACAFTOR; IVACAFTOR,CHEMBL3544914; CHEMBL2010601,ENSG00000001626; ENSG00000001626,Vertex Pharmaceuticals,CFTR corrector and CFTR potentiator,Other,Other indication,Cystic fibrosis,cystic fibrosis,MONDO_0009061,"P, O, B, F",2018,TRUE,,Severe
Symproic,Naldemedine,NALDEMEDINE,CHEMBL2105755,ENSG00000112038,Shionogi,Opioid antagonist,Other,Other indication,Opioid-induced constipation,Constipation,HP_0002019,S,2017,FALSE,Symptomatic,Non severe
TPOXX,Tecovirimat,TECOVIRIMAT,CHEMBL1257073,NA,SIGA Technologies,Viral p37 protein inhibitor,Other,No human target,Smallpox,smallpox,MONDO_0004651,"P, O, F",2018,NA,,Severe
Tabrecta,Capmatinib,CAPMATINIB,CHEMBL3188267,ENSG00000105976,Novartis,MET kinase inhibitor,Oncology,Oncology,NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A",2020,TRUE,,Severe
Tafinlar,Dabrafenib,DABRAFENIB,CHEMBL2028663,ENSG00000157764,GSK,"Kinase inhibitor with activity against BRAFV600E, BRAFV600K, BRAFV600D, wild-type BRAF and other kinases",Oncology,Oncology,Unresectable or metastatic melanoma with BRAF(V600E) mutation as detected by an FDA-approved test,metastatic melanoma,EFO_0002617,"S, O, F",2013,TRUE,,Severe
Tagrisso,Osimertinib,OSIMERTINIB,CHEMBL3353410,ENSG00000146648,AstraZeneca,EGFR inhibitor,Oncology,Oncology,NSCLC with EGFRT790M mutations,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A, F",2015,TRUE,,Severe
Takhzyro,Lanadelumab,LANADELUMAB,CHEMBL3545189,ENSG00000164344,Dyax/Shire,Kallikrein antibody,Other,Other indication,Hereditary angioedema,hereditary angioedema,MONDO_0019623,"P, O, B, F",2018,FALSE,,Severe
Taltz,Ixekizumab,IXEKIZUMAB,CHEMBL1743034,ENSG00000112115,Eli Lilly,IL-17A antagonist,Other,Other indication,Plaque psoriasis,psoriasis vulgaris,EFO_1001494,S,2016,FALSE,,Non severe
Talzenna,Talazoparib,TALAZOPARIB,CHEMBL3137320,"ENSG00000143799, ENSG00000129484",Pfizer,PARP inhibitor,Oncology,Oncology,BRCA-mutated HER2-negative breast cancer,HER2 negative breast carcinoma,EFO_0009780,P,2018,TRUE,,Severe
Tanzeum,Albiglutide,ALBIGLUTIDE,CHEMBL2107841,ENSG00000112164,GlaxoSmithKline,GLP1-receptor agonist,Other,Other indication,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,S,2014,TRUE,,Non Severe
Tavalisse,Fostamatinib,FOSTAMATINIB,CHEMBL2103830,ENSG00000165025,Rigel Pharmaceuticals,SYK inhibitor,Other,Other indication,Immune thrombocytopenic purpura,autoimmune thrombocytopenic purpura,EFO_0007160,"S, O",2018,TRUE,,Severe
Tavneos,Avacopan,Avacopan,CHEMBL3989871,ENSG00000197405,ChemoCentryx,Complement 5a receptor antagonist,Other,Other indication,ANCA-associated vasculitis,Anti-neutrophil cytoplasmic antibody-associated vasculitis,MONDO_0015492,"S, O",2021,FALSE,,Severe
Tazverik,Tazemetostat,TAZEMETOSTAT,CHEMBL3414621,ENSG00000106462,Epizyme,EZH2 inhibitor,Oncology,Oncology,Epithelioid sarcoma,epithelioid sarcoma,MONDO_0017387,"P, O, A, F",2020,TRUE,,Severe
Tecentriq,Atezolizumab,ATEZOLIZUMAB,CHEMBL3707227,ENSG00000120217,Genentech,PDL1 inhibitor,Oncology,Oncology,Urothelial carcinoma,urothelial carcinoma,EFO_0008528,"P, B, A",2016,TRUE,,Severe
Tecfidera,Dimethyl fumarate,DIMETHYL FUMARATE,CHEMBL2107333,ENSG00000079999,Biogen Idec,MOA unknown; activates NRF2 pathway,Other,Other indication,Relapsing forms of multiple sclerosis,relapsing-remitting multiple sclerosis,EFO_0003929,S,2013,TRUE,,Severe
Tecvayli,Teclistamab,Teclistamab,CHEMBL4594505,"ENSG00000048462, ENSG00000160654, ENSG00000198851, ENSG00000167286",J&J,BCMA _ CD3 bispecific antibody,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O, B, A",2022,TRUE,,Severe
Tegsedi,Inotersen,INOTERSEN,CHEMBL4297770,ENSG00000118271,Ionis Pharmaceuticals,TTR-directed antisense oligonucleotide,Other,Other indication,Hereditary TTR-mediated amyloidosis,hereditary ATTR amyloidosis,MONDO_0017132,"P, O, F",2018,TRUE,,Severe
Tepezza,Teprotumumab,TEPROTUMUMAB,CHEMBL1743079,ENSG00000140443,Horizon Therapeutics,IGF1R-directed mAb,Other,Other indication,Thyroid eye disease,Graves disease,EFO_0004237,"P, O, B, F",2020,FALSE,,Not concordant
Tepmetko,Tepotinib,Tepotinib,CHEMBL3402762,ENSG00000105976,EMD Serono,MET kinase inhibitor,Oncology,Oncology,NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, A",2021,TRUE,,Severe
Terlivaz,Terlipressin,Terlipressin,CHEMBL2135460,ENSG00000166148,Mallinckrodt,Vasopressin receptor agonist,Other,Other indication,Kidney function in hepatorenal syndrome,Hepatorenal syndrome,MONDO_0001382,"P, O, F",2022,FALSE,,Severe
Tezspire,Tezepelumab,Tezepelumab,CHEMBL3707229,ENSG00000145777,Astrazeneca/Amgen,TSLP-targeted mAb,Other,Other indication,Severe asthma,asthma,MONDO_0004979,P,2021,TRUE,,Severe
Tibsovo,Ivosidenib,IVOSIDENIB,CHEMBL3989958,ENSG00000138413,Agios Pharmaceuticals,IDH1 inhibitor,Oncology,Oncology,"IDH1-mutated AML, Locally Advanced or Metastatic Cholangiocarcinoma (*)",acute myeloid leukemia; cholangiocarcinoma,EFO_0000222; EFO_0005221,"P, O, F",2018,TRUE,,Severe
Tissueblue,Brilliant Blue G,BRILLIANT BLUE G,CHEMBL4173394,NA,Dutch Ophthalmic Research,Brilliant Blue G dye,Other,No human target,Staining the internal limiting membrane,NA,NA,"P, O",2019,NA,,NA
Tivdak,Tisotumab vedotin,Tisotumab vedotin,CHEMBL4297841,"ENSG00000117525, ENSG00000167552, ENSG00000258947, ENSG00000137267, ENSG00000188229, ENSG00000176014, ENSG00000261456, ENSG00000123416, ENSG00000198033, ENSG00000196230, ENSG00000167553, ENSG00000152086, ENSG00000104833, ENSG00000137285, ENSG00000101162, ENSG00000127824",Seagen/Genmab,Tissue-factor-directed ADC,Oncology,Oncology,Cervical cancer,cervical cancer,MONDO_0002974,"P, A",2021,TRUE,,Severe
Tivicay,Dolutegravir,DOLUTEGRAVIR,CHEMBL1229211,NA,ViiV,HIV1 integrase strand transfer inhibitor,Other,No human target,"HIV1 infection in adults and children, in combination with other antiretroviral agents",HIV infection,EFO_0000764,"P, F",2013,NA,,Severe
Tremfya,Guselkumab,GUSELKUMAB,CHEMBL2364648,"ENSG00000113302, ENSG00000110944",Janssen/Johnson & Johnson,IL-23 blocker,Other,Other indication,Plaque psoriasis,psoriasis vulgaris,EFO_1001494,P,2017,TRUE,,Non severe
Tresiba,Insulin degludec,INSULIN DEGLUDEC,CHEMBL2107869,ENSG00000171105,Novo Nordisk,Long-acting insulin,Other,Other indication,Diabetes,diabetes mellitus,EFO_0000400,S,2015,TRUE,,Severe
Trikafta,Tezacaftor; elexacaftor; ivacaftor,TEZACAFTOR; ELEXACAFTOR; IVACAFTOR,CHEMBL3544914; CHEMBL4298128; CHEMBL2010601,ENSG00000001626; ENSG00000001626; ENSG00000001626,Vertex,Two CFTR correctors and a CFTR potentiator,Other,Other indication,Most common gene mutation that causes cystic fibrosis,cystic fibrosis,MONDO_0009061,"P, O, B, F",2019,TRUE,,Severe
Trodelvy,Sacituzumab govitecan,SACITUZUMAB GOVITECAN,CHEMBL3545262,"ENSG00000198900, ENSG00000184292",Immunomedics/Gilead,"TROP2-directed ADC, with topoisomerase inhibitor",Oncology,Oncology,Triple-negative breast cancer (and advanced or metastatic urothelial cancer (mUC)*),triple-negative breast cancer; urothelial carcinoma,EFO_0005537; EFO_0008528,"P, B, A, F",2020,TRUE,,Severe
Trogarzo,Ibalizumab,IBALIZUMAB,CHEMBL1743029,ENSG00000010610,TaiMed Biologics/Theratechnologies,CD4 antibody,Other,Other indication,HIV,hiv infection,EFO_0000764,"P, O, B, F",2018,TRUE,,Severe
Trulance,Plecanatide,PLECANATIDE,CHEMBL2103867,ENSG00000070019,Synergy Pharmaceuticals,Guanylate cyclase C agonist,Other,Other indication,Chronic idiopathic constipation,Chronic constipation,HP_0012450,S,2017,FALSE,,Non severe
Trulicity,Dulaglutide,DULAGLUTIDE,CHEMBL2108027,ENSG00000112164,Eli Lilly,GLP1-receptor agonist,Other,Other indication,Type 2 diabetes,type 2 diabetes mellitus,MONDO_0005148,S,2014,TRUE,,Non Severe
Truseltiq,Infigratinib,Infigratinib,CHEMBL1852688,"ENSG00000160867, ENSG00000068078, ENSG00000066468, ENSG00000077782",BridgeBio,FGFR2 kinase inhibitor,Oncology,Oncology,FGFR2-mutated bile duct cancer,bile duct cancer,MONDO_0003059,"P, O, A, F",2021,TRUE,,Severe
Tukysa,Tucatinib,TUCATINIB,CHEMBL3989868,ENSG00000141736,Seagen,HER2 kinase inhibitor,Oncology,Oncology,HER2-positive breast cancer,HER2 Positive Breast Carcinoma,EFO_1000294,"P, O, B, F",2020,TRUE,,Severe
Turalio,Pexidartinib,PEXIDARTINIB,CHEMBL3813873,"ENSG00000182578, ENSG00000122025, ENSG00000157404",Daiichi Sankyo,"CSF1R, KIT and FLT3 inhibitor",Oncology,Oncology,Tenosynovial giant cell tumour,Tenosynovial Giant Cell Tumor,EFO_1000562,"P, O, B",2019,TRUE,,Severe
Tymlos,Abaloparatide,ABALOPARATIDE,CHEMBL3301581,ENSG00000160801,Radius Health,Parathyroid hormone-related protein,Other,Other indication,Osteoporosis,osteoporosis,EFO_0003882,S,2017,TRUE,,Non severe
Tzield,Teplizumab,Teplizumab,CHEMBL1743078,ENSG00000198851,Provention Bio,CD3-targeted antibody,Other,Other indication,Delay onset of type 1 diabetes,type 1 diabetes mellitus,MONDO_0005147,"P, B",2022,TRUE,,Severe
Ubrelvy,Ubrogepant,UBROGEPANT,CHEMBL2364638,ENSG00000064989,Allergan,CGRP receptor antagonist,Other,Other indication,Migraine with or without aura,migraine disorder,MONDO_0005277,S,2019,TRUE,,Non Severe
Ukoniq,Umbralisib,Umbralisib,CHEMBL3948730,"ENSG00000171608, ENSG00000097007, ENSG00000213923",TG Therapeutics,PI3Kdelta and CK1epsilon inhibitor,Oncology,Oncology,"MZL, follicular lymphoma",MZL; follicular lymphoma,EFO_1000630; MONDO_0018906,"P, O, B, A",2021,TRUE,,Severe
Ultomiris,Ravulizumab,RAVULIZUMAB,CHEMBL3989986,ENSG00000106804,Alexion,Complement inhibitor,Other,Other indication,"Paroxysmal nocturnal haemoglobinuria, atypical hemolytic uremic syndrome (*), generalized myasthenia gravis AChR+ (*)","paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, Myasthenia gravis",MONDO_0100244; MONDO_0016244; EFO_0004991,"S, O",2018,TRUE,,Severe
Unituxin,Dinutuximab,DINUTUXIMAB,CHEMBL3137342,NA,United Therapeutics,GD2-binding mAb,Oncology,,Neuroblastoma,neuroblastoma,EFO_0000621,"P, O",2015,NA,,Severe
Uplizna,Inebilizumab,INEBILIZUMAB,CHEMBL2109334,ENSG00000177455,Viela Bio,CD19-directed mAb,Other,Other indication,NMOSD,neuromyelitis optica,EFO_0004256,"S, O, B",2020,FALSE,,Severe
Uptravi,Selexipag,SELEXIPAG,CHEMBL238804,ENSG00000160013,Actelion,Prostacyclin receptor agonist,Other,Other indication,Pulmonary arterial hypertension,pulmonary arterial hypertension,EFO_0001361,"S, O",2015,FALSE,,Severe
Vabomere,Meropenem; vaborbactam,MEROPENEM; VABORBACTAM,CHEMBL127; CHEMBL3317857,NA; NA,The Medicines Company/Rempex Pharmaceuticals,Carbapenem antimicrobial plus a ‚Äö√¢√†‚àö‚â†‚Äö√Ñ√∂‚àö¬¢¬¨√ü-lactamase inhibitor,Other,No human target,Complicated urinary tract infections,urinary tract infection,EFO_0003103,"P, F",2017,NA,,Non Severe
Vabysmo,Faricimab,Faricimab,CHEMBL4297750,"ENSG00000112715, ENSG00000091879",Roche/Genentech,VEGF _ ANG2 bispecific antibody,Other,Other indication,nAMD and DME,age-related macular degeneration,EFO_0001365,S,2022,TRUE,,Non Severe
Varubi,Rolapitant,ROLAPITANT,CHEMBL3707331,ENSG00000115353,Tesaro,Neurokinin 1 receptor antagonist,Other,Other indication,Nausea and vomiting associated with chemotherapy,Chemotherapy-induced nausea and vomiting,EFO_0006911,S,2015,FALSE,Symptomatic,Non Severe
Veklury,Remdesivir,REMDESIVIR,CHEMBL4065616,NA,Gilead,Nucleotide analogue RNA polymerase inhibitor,Other,No human target,COVID-19,covid-19,MONDO_0100096,"P, F",2020,NA,,Severe
Veltassa,Patiromer sorbitex,PATIROMER SORBITEX,CHEMBL2107840,NA,Relypsa,Potassium binder,Other,No human target,Hyperkalaemia,Hyperkalemia,HP_0002153,S,2015,NA,,Not concordant
Venclexta,Venetoclax,VENETOCLAX,CHEMBL3137309,ENSG00000171791,AbbVie,BCL-2 inhibitor,Oncology,Oncology,Chronic lymphocytic leukaemia,chronic lymphocytic leukemia,EFO_0000095,"P, O, B, A",2016,TRUE,,Severe
Verquvo,Vericiguat,Vericiguat,CHEMBL4066936,"ENSG00000123201, ENSG00000061918, ENSG00000152402, ENSG00000164116",Merck & Co./Bayer,sGC stimulator,Other,Other indication,Chronic heart failure,coronary artery disease,EFO_0001645,"P, F",2021,TRUE,,Severe
Verzenio,Abemaciclib,ABEMACICLIB,CHEMBL3301610,"ENSG00000105810, ENSG00000135446",Eli Lilly,CDK4/6 inhibitor,Oncology,Oncology,"HR-positive, HER2-negative breast cancer",HER2 negative breast carcinoma,EFO_0009780,"P, B, F",2017,TRUE,,Severe
Viberzi,Eluxadoline,ELUXADOLINE,CHEMBL2159122,ENSG00000112038,Allergan,Mu-opioid receptor agonist,Other,Other indication,Irritable bowel syndrome,irritable bowel syndrome,EFO_0000555,"P, F",2015,FALSE,Symptomatic,Non severe
Viekira Pak,Ombitasvir; paritaprevir; dasabuvir; ritonavir,OMBITASVIR; PARITAPREVIR; DASABUVIR; RITONAVIR,CHEMBL3127326; CHEMBL3391662; CHEMBL3137312; CHEMBL163,"NA; NA; NA; ENSG00000021461, ENSG00000160870, ENSG00000106258, ENSG00000160868",AbbVie,An NS5A inhibitor plus an NS3A- and NS4A-protease inhibitor plus a non-nucleoside NS5B-palm-polymerase inhibitor plus a CYP3A inhibitor,Other,Other indication,Chronic HCV genotype 1 infection,hepatitis C virus infection,EFO_0003047,"P, B, F",2014,NA,,Severe
Viltepso,Viltolarsen,VILTOLARSEN,CHEMBL4298062,ENSG00000198947,Nippon Shinyaku,Dystrophin splicing modifier,Other,Other indication,Duchenne muscular dystrophy,duchenne muscular dystrophy,MONDO_0010679,"P, O, A, F",2020,TRUE,,Severe
Vimizim,Elosulfase alfa,ELOSULFASE ALFA,CHEMBL2108676,ENSG00000141012,BioMarin,Hydrolytic lysosomal glycosaminoglycan-specific enzyme,Other,Other indication,Mucopolysaccharidosis type IVA,mucopolysaccharidosis type 4A,MONDO_0009659,"P, O, F",2014,TRUE,,Severe
Vitrakvi,Larotrectinib,LAROTRECTINIB,CHEMBL3889654,"ENSG00000148053, ENSG00000198400, ENSG00000140538",Loxo Oncology/Bayer,"TRKA, TRKB and TRKC inhibitor",Oncology,Oncology,NTRK-positive solid cancers,salivary gland cancer; soft tissue sarcoma; thyroid cancer,MONDO_0004669; EFO_1001968; MONDO_0002108,"P, O, B, A",2018,TRUE,,Severe
Vivjoa,Oteseconazole,Oteseconazole,CHEMBL3311228,NA,Mycovia,Azole antifungal,Other,No human target,Vulvovaginal candidiasis,vulvovaginal candidiasis,EFO_0007543,"P, F",2022,NA,,NA
Vizamyl,Flutemetamol F-18,FLUTEMETAMOL F-18,CHEMBL2042122,ENSG00000142192,GE Healthcare,Radioactive diagnostic agent,Other,Other indication,PET imaging of the brain to estimate beta-amyloid neuritic plaque density in patients who are being evaluated for Alzheimer's disease,neuritic plaque measurement; Alzheimer disease,EFO_0006798; MONDO_0004975,S,2013,TRUE,Imaging,Severe
Vizimpro,Dacomitinib,DACOMITINIB,CHEMBL2105719,"ENSG00000178568, ENSG00000146648, ENSG00000141736",Pfizer,EGFR inhibitor,Oncology,Oncology,EGFR-mutated NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O",2018,TRUE,,Severe
Vonjo,Pacritinib,Pacritinib,CHEMBL2035187,"ENSG00000096968, ENSG00000122025",CTI Biopharma,JAK2 inhibitor,Oncology,Oncology,Myelofibrosis,myelofibrosis,MONDO_0044903,"P, O, A, F",2022,TRUE,,Severe
Voquezna Triple Pak,Vonoprazan; amoxicillin; clarithromycin,Vonoprazan; amoxicillin; clarithromycin,CHEMBL2079130; CHEMBL1082; CHEMBL1741,"ENSG00000186009, ENSG00000105675; NA; NA",Phathom,Potassium-competitive acid blocker plus a penicillin class antibacterial plus a macrolide antimicrobial,Other,Other indication,Helicobacter pylori infection,Helicobacter pylori infectious disease,EFO_1000961,"P, F",2022,NA,,Non Severe
Vosevi,Sofosbuvir; velpatasvir; voxilaprevir,SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR,CHEMBL1259059; CHEMBL3545062; CHEMBL3707372,NA; NA; NA,Gilead Sciences,Nucleotide analogue NS5B polymerase inhibitor plus an NS5A inhibitor plus an NS3/4A protease inhibitor,Other,No human target,HCV,hepatitis C virus infection,EFO_0003047,"P, B",2017,NA,,Severe
Voxzogo,Vosoritide,Vosoritide,CHEMBL3707276,ENSG00000159899,Biomarin,CNP analogue,Other,Other indication,Achondroplasia,achondroplasia,MONDO_0007037,"P, O, A",2021,TRUE,,Non Severe
Vraylar,Cariprazine,CARIPRAZINE,CHEMBL2028019,"ENSG00000151577, ENSG00000149295",Forest,Atypical antipsychotic,Other,Other indication,Schizophrenia and bipolar 1 disorder,Schizophrenia; bipolar disorder,MONDO_0005090; MONDO_0004985,S,2015,TRUE,,Severe
Vtama,Tapinarof,Tapinarof,CHEMBL259571,ENSG00000106546,Dermavant,Aryl hydrocarbon receptor agonist,Other,Other indication,Plaque psoriasis,psoriasis vulgaris,EFO_1001494,S,2022,TRUE,,Non severe
Vyepti,Eptinezumab,EPTINEZUMAB,CHEMBL3833320,"ENSG00000110680, ENSG00000175868",Lundbeck,CGRP-directed mAb,Other,Other indication,Migraine,migraine disorder,MONDO_0005277,S,2020,TRUE,,Non Severe
Vyleesi,Bremelanotide,BREMELANOTIDE,CHEMBL2070241,ENSG00000166603,Amag,Melanocortin receptor agonist,Other,Other indication,Hypoactive sexual desire disorder,sexual dysfunction,EFO_0004714,S,2019,TRUE,,Non Severe
Vyndaqel,Tafamidis,TAFAMIDIS,CHEMBL2103837,ENSG00000118271,Pfizer/Foldrx,Transthyretin stabilizer,Other,Other indication,Heart disease caused by ATTR-CM,cardiomyopathy,EFO_0000318,"P, O, B, F",2019,TRUE,,Severe
Vyondys 53,Golodirsen,GOLODIRSEN,CHEMBL4297762,ENSG00000198947,Sarepta,Exon 53 skipping antisense,Other,Other indication,Duchenne muscular dystrophy,duchenne muscular dystrophy,MONDO_0010679,"P, O, A, F",2019,TRUE,,Severe
Vyvgart,Efgartigimod alfa,Efgartigimod alfa,CHEMBL4297551,ENSG00000104870,Argenx,FcRn-binding Fc fragment,Other,Other indication,Myasthenia gravis,Myasthenia gravis,EFO_0004991,"S, O, F",2021,FALSE,,Severe
Vyzulta,Latanoprostene bunod,LATANOPROSTENE BUNOD,CHEMBL2364612,ENSG00000122420,Bausch and Lomb/Valeant Pharmaceuticals,Prostaglandin analogue,Other,Other indication,Intraocular pressure,intraocular pressure measurement,EFO_0004695,S,2017,FALSE,,Non Severe
Wakix,Pitolisant,PITOLISANT,CHEMBL462605,ENSG00000101180,Harmony,H3-receptor antagonist/inverse agonist,Other,Other indication,Excessive sleepiness due to narcolepsy,narcolepsy,MONDO_0021107,"P, O, F",2019,FALSE,Symptomatic,Severe
Welireg,Belzutifan,Belzutifan,CHEMBL4585668,ENSG00000116016,Merck & Co.,HIF-2alpha inhibitor,Oncology,Oncology,von Hippel-Lindau disease,von Hippel-Lindau disease,MONDO_0008667,"P, O",2021,TRUE,,Severe
Winlevi,Clascoterone,CLASCOTERONE,CHEMBL3590187,ENSG00000169083,Cassiopea SpA,Androgen receptor inhibitor,Other,Other indication,Acne vulgaris,acne,EFO_0003894,S,2020,TRUE,,Non Severe
Xadago,Safinamide,SAFINAMIDE,CHEMBL396778,ENSG00000069535,US WorldMeds,MAO-B inhibitor,Other,Other indication,Parkinson disease,Parkinson disease,MONDO_0005180,S,2017,TRUE,,Severe
Xcopri,Cenobamate,CENOBAMATE,CHEMBL3989949,"ENSG00000168356, ENSG00000196876, ENSG00000185313, ENSG00000144285, ENSG00000153253, ENSG00000183873, ENSG00000136531, ENSG00000169432, ENSG00000136546, ENSG00000007314, ENSG00000186297, ENSG00000151834, ENSG00000011677, ENSG00000187730, ENSG00000109158, ENSG00000022355, ENSG00000166206, ENSG00000182256, ENSG00000145864, ENSG00000268089, ENSG00000145863, ENSG00000094755, ENSG00000163288, ENSG00000113327, ENSG00000102287, ENSG00000163285",SK Life Science,Unknown,Other,Other indication,Partial onset seizures,seizure,HP_0001250,S,2019,TRUE,,Not concordant
Xeglyze,Abametapir,ABAMETAPIR,CHEMBL2205807,NA,Dr Reddy‚Äö√Ñ√∂‚àö√ë‚àö‚àÇ‚Äö√†√∂‚àö√´‚Äö√†√∂‚Äö√†√á‚Äö√Ñ√∂‚àö‚Ä†‚àö‚àÇ‚Äö√†√∂‚àö¬¥‚Äö√Ñ√∂‚àö‚Ä†‚àö‚àÇ¬¨¬®‚Äö√Ñ¬¢s,Metalloproteinase inhibitor,Other,No human target,Head lice,lice infestation,MONDO_0003472,S,2020,NA,,Non Severe
Xenleta,Lefamulin,LEFAMULIN,CHEMBL3291398,NA,Nabriva,Pleuromutilin antibacterial,Other,No human target,CABP,bacterial pneumonia,EFO_1001272,"P, F",2019,NA,,Severe
Xenoview,Xenon Xe 129 hyperpolarized,Xenon Xe 129 hyperpolarized,CHEMBL4594411,NA,Polarean,Hyperpolarized contrast agent,Other,No human target,MRI-evaluation of lung ventilation,NA,NA,S,2022,NA,,NA
Xenpozyme,Olipudase alfa,Olipudase alfa,CHEMBL3707358,ENSG00000166311,Sanofi/Genzyme,Acid sphingomyelinase ERT,Other,Other indication,Acid sphingomyelinase deficiency,acid sphingomyelinase deficiency,MONDO_0100464,"P, O, B, F",2022,TRUE,,Severe
Xepi,Ozenoxacin,OZENOXACIN,CHEMBL3990047,NA,Ferrer Internacional,Quinolone antimicrobial,Other,No human target,Impetigo due to Staphylococcus aureus or Streptococcus pyogenes,impetigo,EFO_1000714,S,2017,NA,,Non Severe
Xerava,Eravacycline,ERAVACYCLINE,CHEMBL1951095,NA,Tetraphase Pharmaceuticals,Tetracycline antibiotic,Other,No human target,Complicated intra-abdominal infections,infectious disease,EFO_0005741,"P, F",2018,NA,,Severe
Xermelo,Telotristat etiprate,TELOTRISTAT ETIPRATE,CHEMBL3348963,"ENSG00000129167, ENSG00000139287",Lexicon Pharmaceuticals,Tryptophan hydroxylase inhibitor,Other,Other indication,Carcinoid syndrome diarrhoea,carcinoid syndrome; Diarrhea,EFO_1000852; HP_0002014,"P, O, F",2017,FALSE,Symptomatic,Non Severe
Xiidra,Lifitegrast,LIFITEGRAST,CHEMBL2048028,"ENSG00000160255, ENSG00000005844",Shire Pharmaceuticals,LFA1 antagonist,Other,Other indication,Dry eye disease,dry eye syndrome,EFO_1000906,P,2016,FALSE,,Non Severe
Xofigo,Radium RA 223 dichloride,RADIUM RA 223 DICHLORIDE,CHEMBL2107816,NA,Bayer,Alpha particle-emitting radioactive therapeutic,Other,No human target,Castration-resistant prostate cancer,prostate cancer,MONDO_0008315,"P, F",2013,NA,,Severe
Xofluza,Baloxavir marboxil,BALOXAVIR MARBOXIL,CHEMBL4297503,NA,Shionogi/Roche,Polymerase acidic endonuclease inhibitor,Other,No human target,Acute uncomplicated influenza,influenza,EFO_0007328,P,2018,NA,,Non Severe
Xospata,Gilteritinib,GILTERITINIB,CHEMBL3301622,"ENSG00000122025, ENSG00000167601",Astellas,FLT3 inhibitor,Oncology,Oncology,FLT3-positive AML,acute myeloid leukemia,EFO_0000222,"P, O, B, F",2018,TRUE,,Severe
Xpovio,Selinexor,SELINEXOR,CHEMBL3545185,ENSG00000082898,Karyopharm Therapeutics,XPO1 inhibitor,Oncology,Oncology,Multiple myeloma,multiple myeloma,EFO_0001378,"P, O, A, F",2019,TRUE,,Severe
Xtoro,Finafloxacin,FINAFLOXACIN,CHEMBL1908370,NA,Alcon,Fluoroquinolone antimicrobial,Other,No human target,Acute otitis externa (swimmer's ear),otitis externa,EFO_0009560,P,2014,NA,,Non Severe
Xuriden,Uridine,URIDINE,CHEMBL100259,NA,Wellstat,Pyrimidine analogue,Other,No human target,Hereditary orotic aciduria,Hereditary orotic aciduria,Orphanet_30,"P, O, B",2015,NA,,Severe
Yondelis,Trabectedin,TRABECTEDIN,CHEMBL450449,NA,Johnson & Johnson,Alkylating drug,Oncology,,Liposarcoma or leiomyosarcoma,liposarcoma; leiomyosarcoma,EFO_0000569; EFO_0000564,"P, O",2015,NA,,Severe
Yupelri,Revefenacin,REVEFENACIN,CHEMBL3833319,ENSG00000133019,Theravance Biopharma/Mylan,Long-acting muscarinic receptor antagonist,Other,Other indication,COPD,chronic obstructive pulmonary disease,EFO_0000341,S,2018,TRUE,,Severe
Zegalogue,Dasiglucagon,Dasiglucagon,CHEMBL4297741,ENSG00000215644,Zealand Pharma,Glucagon receptor agonist,Other,Other indication,Severe hypoglycaemia,GCGR-related hyperglucagonemia,EFO_0001360,S,2021,FALSE,,Severe
Zejula,Niraparib,NIRAPARIB,CHEMBL1094636,"ENSG00000129484, ENSG00000143799",Tesaro,PARP inhibitor,Oncology,Oncology,"Epithelial ovarian, fallopian tube or primary peritoneal cancer",fallopian tube cancer; ovarian epithelial tumor; primary peritoneal carcinoma,MONDO_0002158; MONDO_0002229; MONDO_0015686,"P, O, B, F",2017,TRUE,,Severe
Zemdri,Plazomicin,PLAZOMICIN,CHEMBL1650559,NA,Achaogen,Aminoglycoside antibacterial,Other,No human target,Urinary tract infections,urinary tract infection,EFO_0003103,P,2018,NA,,Non Severe
Zepatier,Elbasvir; grazoprevir,ELBASVIR; GRAZOPREVIR,CHEMBL3039514; CHEMBL2063090,NA; NA,Merck & Co.,NS5A inhibitor plus NS3/4A protease inhibitor,Other,No human target,HCV genotypes 1 and 4,hepatitis C virus infection,EFO_0003047,"P, B",2016,NA,,Severe
Zeposia,Ozanimod,OZANIMOD,CHEMBL3707247,ENSG00000170989,Celgene/Bristol Myers Squibb,S1P receptor modulator,Other,Other indication,Multiple sclerosis,multiple sclerosis,MONDO_0005301,S,2020,TRUE,,Severe
Zepzelca,Lurbinectedin,LURBINECTEDIN,CHEMBL4297516,NA,Jazz,Alkylating drug,Oncology,,Small-cell lung cancer,small cell lung carcinoma,EFO_0000702,"P, O, A",2020,NA,,Severe
Zerbaxa,Ceftolozane; tazobactam,CEFTOLOZANE; TAZOBACTAM,CHEMBL2103872; CHEMBL404,NA; NA,Cubist,A cephalosporin antibacterial plus a beta-lactamase inhibitor,Other,No human target,Complicated intra-abdominal infections and complicated urinary tract infections,infection,EFO_0000544,"P, F",2014,NA,,Severe
Zinbryta,Daclizumab,DACLIZUMAB,CHEMBL1201605,"ENSG00000134460, ENSG00000100385, ENSG00000147168",Biogen,IL-2-targeted mAb,Other,Other indication,Multiple sclerosis,multiple sclerosis,MONDO_0005301,S,2016,TRUE,,Severe
Zinplava,Bezlotoxumab,BEZLOTOXUMAB,CHEMBL2108670,NA,Merck & Co.,mAb against Clostridium difficile toxin,Other,No human target,C. difficile recurrence,clostridium difficile infection,EFO_0009130,"P, F",2016,NA,,Severe
Zokinvy,Lonafarnib,LONAFARNIB,CHEMBL298734,"ENSG00000257365, ENSG00000168522",Eiger,Farnesyltransferase inhibitor,Other,Other indication,HGPS,hutchinson-gilford progeria syndrome,MONDO_0008310,"P, O, B",2020,FALSE,,Severe
Zontivity,Vorapaxar,VORAPAXAR,CHEMBL493982,ENSG00000181104,Merck & Co.,Protease-activated receptor 1 antagonist,Other,Other indication,Thrombotic cardiovascular events (after myocardial infarction or with peripheral arterial disease*),myocardial infarction; peripheral arterial disease,EFO_0000612; EFO_0004265,"S, F",2014,FALSE,,Severe
Ztalmy,Ganaxolone,Ganaxolone,CHEMBL1568698,"ENSG00000094755, ENSG00000163288, ENSG00000102287, ENSG00000166206, ENSG00000145863, ENSG00000022355, ENSG00000113327, ENSG00000187730, ENSG00000011677, ENSG00000268089, ENSG00000145864, ENSG00000151834, ENSG00000186297, ENSG00000182256, ENSG00000109158, ENSG00000163285",Marinus,GABAA receptor positive allosteric modulator,Other,Other indication,Seizures associated with CDD,Epileptic encephalopathy,HP_0200134,"P, O",2022,TRUE,,Severe
Zulresso,Brexanolone,BREXANOLONE,CHEMBL207538,"ENSG00000094755, ENSG00000109158, ENSG00000186297, ENSG00000022355, ENSG00000145864, ENSG00000166206, ENSG00000182256, ENSG00000011677, ENSG00000268089, ENSG00000102287, ENSG00000113327, ENSG00000163285, ENSG00000151834, ENSG00000145863, ENSG00000163288, ENSG00000187730",Sage Therapeutics,GABAA-receptor-positive modulator,Other,Other indication,Postpartum depression,postpartum depression,EFO_0007453,"P, B",2019,TRUE,,Not concordant
Zurampic,Lesinurad,LESINURAD,CHEMBL2105720,ENSG00000197891,AstraZeneca,URAT1 inhibitor,Other,Other indication,Gout,gout,EFO_0004274,S,2015,TRUE,,Non Severe
Zydelig,Idelalisib,IDELALISIB,CHEMBL2216870,ENSG00000171608,Gilead Sciences,PI3K‚Äöp110-delta subunit inhibitor,Other,Other indication,"CLL, B-cell non-Hodgkin lymphoma and SLL",chronic lymphocytic leukemia; B-cell non-Hodgkins lymphoma,EFO_0000095; EFO_1001938,"P, O, B, A, F",2014,TRUE,,Severe
Zykadia,Ceritinib,CERITINIB,CHEMBL2403108,"ENSG00000171094, ENSG00000143924, ENSG00000181163",Novartis,"Kinase inhibitor against ALK, IGF1R, insulin receptor and ROS1",Oncology,Oncology,ALK-positive metastatic NSCLC,non-small cell lung carcinoma,EFO_0003060,"P, O, B, A",2014,TRUE,,Severe
Zynlonta,Loncastuximab tesirine,Loncastuximab tesirine,CHEMBL4297778,ENSG00000177455,ADC Therapeutics,CD19-targeted ADC,Oncology,Oncology,B-cell lymphoma,B-cell non-Hodgkins lymphoma,EFO_1001938,"P, O, A",2021,TRUE,,Severe